US Pat. No. 10,918,882

ORAL TREATMENT DEVICE

Colgate-Palmolive Company...

1. An oral treatment device comprising:an intraoral mouthpiece comprising:
a first light emitting surface configured to emit light onto a user's maxillary teeth, the first light emitting surface being a smooth exposed surface having a concave curvature;
a second light emitting surface configured to emit light onto a user's mandibular teeth, the second light emitting surface being a smooth exposed surface having a concave curvature;
the first and second light emitting surfaces located on opposite sides of a horizontal reference plane;
the first light emitting surface inclined so that a first acute angle is formed between the first light emitting surface and the horizontal reference plane;
the second light emitting surface inclined so that a second acute angle is formed between the second light emitting surface and the horizontal reference plane; and
a first lamp and a second lamp, the first and second lamps operably coupled to a control circuit having a power source, each of the first and second lamps comprising:
a flexible sheet body having a front surface and a rear surface;
a plurality of light emitters embedded within the flexible sheet body that generate light which is emitted from the rear surface of the flexible sheet body;
a lamp support structure comprising a lamp support surface having a concave curvature, each of the first and second lamps mounted to the lamp support surface so that the rear surface of the flexible sheet body of each of the first and second lamps assumes a concave curvature, thereby forming a lamp assembly; and
wherein the first light emitting surface is inclined at the first acute angle and the second light emitting surface is inclined at the second acute angle when the intraoral mouthpiece is in an unbiased state;
wherein the first and second acute angles are different;
wherein the first light emitting surface is the rear surface of the flexible sheet body of the first lamp and the second light emitting surface is the rear surface of the flexible sheet body of the second lamp; and
wherein the lamp support surface is a stepped surface having a first riser portion, a tread portion, and a second riser portion, the first lamp mounted to and covering the first riser portion and the second lamp mounted to and covering the second riser portion.

US Pat. No. 10,918,881

EXCHANGEABLE LASER AND ARRAY THEREOF

Hua Shang, Nanjing (CN)

1. An exchangeable laser, comprising a cartridge receiver and a housing, wherein a laser element is fixed inside the cartridge receiver, and the housing is used for clamping the cartridge receiver; the cartridge receiver has a unique optical interface and a plurality of electrical interfaces for docking with the housing;the housing comprises a first accommodating space for accommodating the cartridge receiver, a clamping unit, and a second accommodating space for accommodating the clamping unit;
a front panel of the housing is provided with an insertion port for horizontally inserting the cartridge receiver into the first accommodating space;
the second accommodating space is disposed under the first accommodating space and is communication with the first accommodating space through a clamping port provided on a bottom panel of the first accommodating space;
the clamping unit comprises a clip-lock assembly and a button assembly, the clip-lock assembly comprising a clip-lock panel disposed horizontally and an elastic assembly disposed under the clip-lock panel;
an upper panel of the clip-lock panel is provided with a plurality of cylindrical protrusions with axes inclined rearward, and a lower panel of the cartridge receiver is correspondingly provided with a plurality of cylindrical slots having a same shape as the cylindrical protrusions; male and female electrical interfaces are respectively provided inside the cylindrical protrusions and cylindrical slots;
the cylindrical protrusions pass upward through the clamping port to clamp the cylindrical slots under an action of the elastic assembly, so as to power the laser element;
when the button assembly is moved backward, the clip-lock panel is driven to move obliquely downward along an axial direction of the cylindrical protrusions until the cylindrical protrusions disengage from the cylindrical slots;
when the button assembly is reset forward, the clip-lock panel is moved obliquely upward along the axial direction of the cylindrical protrusions under the action of the elastic assembly until the cylindrical protrusions engage with the cylindrical slots.

US Pat. No. 10,918,880

METHODS AND APPARATUS FOR TREATMENT OF CHRONIC KIDNEY DISEASE

Minnesota Medical Physics...

1. A method of treating chronic kidney disease of a mammal, the method comprising:increasing a concentration of Ata adenosine receptors on cellular membranes in a kidney of the mammal by:
delivering a first pulsed magnetic field with a first polarity to the kidney of the mammal along a first orthogonal direction;
delivering a second pulsed magnetic field with the first polarity to the kidney of the mammal along a second orthogonal direction, the second orthogonal direction being perpendicular to the first orthogonal direction, the first and second orthogonal directions being in a common plane; and
delivering a third pulsed magnetic field with the first polarity to the kidney of the mammal along a third orthogonal direction, the third orthogonal direction being perpendicular to the common plane.

US Pat. No. 10,918,879

WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) SYSTEM REACTING TO HIGH-AMPLITUDE ECG NOISE

West Affum Holdings Corp....

1. A wearable cardioverter defibrillator (WCD) system, comprising:a support structure configured to be worn by an ambulatory patient;
an energy storage module configured to store an electrical charge;
a discharge circuit coupled to the energy storage module;
electrodes configured to sense an Electrocardiogram (ECG) signal of the patient;
a processor configured to:
set a noise-detected flag responsive to the sensed ECG signal meeting a High-Amplitude (H-A) noise criterion, and unset the noise-detected flag responsive to the sensed ECG signal meeting a High-Amplitude (H-A) quiet criterion, wherein the H-A noise criterion is met when a fraction of ECG portions in a group of ECG portions having a potential R peak exceeding a threshold amplitude is greater than a threshold fraction, and the H-A quiet criterion is met when the H-A noise criterion is no longer met;
determine, from the sensed ECG signal, whether a shock criterion is met, and
control, responsive to the shock criterion being met and the noise-detected flag being unset, the discharge circuit to discharge the stored electrical charge through the patient while the support structure is worn by the patient to deliver a shock to the patient, wherein the discharge circuit is controlled to not discharge when the noise-detected flag is set even when it is determined that the shock criterion is met.

US Pat. No. 10,918,878

PRESSURE RESISTANT CONDUCTIVE FLUID CONTAINMENT

West Affum Holdings Corp....

1. A conductive fluid deployment device for use with an electrotherapy system, the device comprising:a reservoir layer;
a plurality of reservoirs disposed on the reservoir layer, each of the plurality of reservoirs comprising a volume of a conductive fluid, wherein at least one of the plurality of reservoirs surrounds a seal;
a controller connected to at least one reservoir in the plurality of reservoirs, the controller configured to control selective delivery of a pressurized fluid to increase a pressure inside the at least one reservoir; and
at least one conductive surface configured to come into contact with the conductive fluid when the conductive fluid evacuates from the reservoir and the conductive surface configured to transfer a therapeutic current to a body of a patient,
wherein a source of the pressurized fluid comprises one of either a gas generator, a pressurized fluid container, or a combination of gas generator and pressurized fluid container.

US Pat. No. 10,918,877

BATTERY LOCK FOR AMBULATORY MEDICAL DEVICE

ZOLL Medical Corporation,...

1. An ambulatory medical device configured to be worn by a patient, the device comprising:at least one physiological sensor configured to couple to the patient, wherein the at least one physiological sensor comprises an ECG sensor configured to detect one or more ECG signals of the patient;
physiological signal circuitry operably connected to the at least one physiological sensor and configured to
receive a physiological signal from the at least one physiological sensor, and
produce a physiological metric based upon the received physiological signal, wherein the physiological metric comprises at least one ECG metric;
therapy delivery circuitry configured to produce, based upon the physiological metric, a therapy shock;
battery lock circuitry configured to
transmit a lock signal at a beginning of a battery lock period of the ambulatory medical device, and
transmit an unlock signal upon detecting an unlock triggering event indicating an end of the battery lock period of the ambulatory medical device;
a battery being configured to be securely disposed within a chamber of the ambulatory medical device in a first locked manner and provide power to the ambulatory medical device; and
a battery lock configured to
mechanically engage the battery in a second locked manner upon receiving the lock signal indicating the beginning of the battery lock period of the ambulatory medical device, and
mechanically disengage the battery from the second locked manner upon receiving the unlock signal signaling the end of the battery lock period.

US Pat. No. 10,918,876

ACTIVE IMPLANTABLE MEDICAL DEVICE FOR DETECTING AND QUANTIFYING FUSION

Sorin CRM SAS, Clamart (...

1. An active implantable medical device comprising:a pulse generator that provides controlled cardiac stimulation;
electrodes coupled to the pulse generator and configured to apply stimulation, sense ventricular and/or atrial depolarization signals, and collect, during a single cardiac cycle, concurrently on separate respective channels of the electrodes, at least two different endocardial electrogram (EGM) signals;
a processor; and
a memory having instructions stored thereon that, when executed by the processor cause the processor to analyze a current cardiac cycle by:
deriving at least two respective distinct temporal components of the at least two different EGM signals;
combining the at least two temporal components in at least one parametric two dimensional (2D) characteristic representative of the current cardiac cycle, from variations of one of the temporal components as a function of another of the temporal components; and
comparing the 2D characteristic of the current cardiac cycle with at least one reference 2D characteristic previously obtained and stored by the device to derive a value of at least one descriptor representative of a similarity between the 2D characteristic of the current cardiac cycle and the reference 2D characteristic,
wherein the instructions further cause the processor to quantify a degree of fusion by:
comparing the 2D characteristic of the current cardiac cycle with a first reference 2D characteristic previously obtained in a complete capture situation and stored by the device, to derive a first value of the at least one descriptor;
comparing the 2D characteristic of the current cycle with a second reference 2D characteristic previously obtained in a situation of ventricular spontaneous rhythm and stored by the device, to derive a second value of the at least one descriptor; and
deriving a metric according to both the first value and the second value,
the metric quantifying a fusion rate in a case of occurrence of a fusion situation, between two respective extrema corresponding to the first and second values respectively obtained in a situation of complete capture and in a situation of spontaneous rhythm.

US Pat. No. 10,918,875

IMPLANTABLE MEDICAL DEVICE WITH A FLUX CONCENTRATOR AND A RECEIVING COIL DISPOSED ABOUT THE FLUX CONCENTRATOR

CARDIAC PACEMAKERS, INC.,...

1. An implantable medical device (IMD) configured to be implanted within a patient, the IMD comprising:a housing configured for trans-catheter deployment;
a plurality of electrodes exposed external to the housing;
therapeutic circuitry configured to sense one or more signals via one or more of the plurality of electrodes and/or to stimulate tissue via one or more of the plurality of electrodes;
a plurality of flux concentrator elements positioned within the housing, each flux concentrator element includes an inner major surface, an outer major surface, and two opposing ends, wherein the plurality of elongated flux concentrator elements are arranged in an end-to-end configuration to collectively form an elongated body that defines an internal cavity;
wherein each of the plurality of flux concentrator elements comprises a magnetically permeable material with a relative permeability (?r) of greater than 10;
a receiving coil disposed around at least a portion of the elongated body, wherein the elongated body operates as a flux concentrator for concentrating an externally generated magnetic flux through the receiving coil to induce a current in the receiving coil;
a rechargeable power source configured to power the therapeutic circuitry, at least part of the rechargeable power source disposed within the internal cavity defined by the elongated body; and
charging circuitry operatively coupled with the receiving coil and the rechargeable power source, the charging circuitry configured to use the current induced in the receiving coil to charge the rechargeable power source.

US Pat. No. 10,918,874

SEALED PACKAGE AND METHOD OF FORMING SAME

Medtronic, Inc., Minneap...

1. A hermetically-sealed package, comprising:a housing that extends along a housing axis between a first end and a second end, wherein the housing comprises first and second opaque portions and a transparent portion disposed between the first and second opaque portions, wherein the first opaque portion is hermetically sealed to a first end of the transparent portion and the second opaque portion is hermetically sealed to a second end of the transparent portion, wherein at least one of the first and second opaque portions is hermetically sealed to the transparent portion by a weld ring;
a power source disposed within the housing; and
an inductive coil disposed at least partially within the transparent portion of the housing and electrically connected to the power source.

US Pat. No. 10,918,873

SYSTEMS AND METHODS FOR MAKING AND USING AN ENHANCED CONNECTOR OF AN ELECTRICAL STIMULATION SYSTEM

BOSTON SCIENTIFIC NEUROMO...

1. An implantable control module for an electrical stimulation system, the control module comprising:a housing;
a connector shell extending into the housing and collectively with the housing forming a sealed cavity, the connector shell having a longitudinal length, a sidewall with a cavity-facing surface, a first end open to an environment external to the housing, and an opposing closed second end, the connector shell defining a connector lumen extending within the connector shell and open at the first end to receive a portion of a lead or lead extension, the connector shell defining a plurality of interconnect apertures through the connector shell, and
a plurality of connector contacts arranged along the connector lumen within the connector shell, wherein each of the connector contacts is aligned with at least one of the interconnect apertures;
an electronic subassembly disposed in the sealed cavity; and
a plurality of interconnect wires electrically coupling the electronic subassembly to the plurality of connector contacts and extending from the connector shell within the sealed cavity, wherein the interconnect wires are either a) directly attached to the connector contacts, b) directly attached to conductive material filling the interconnect apertures and directly attached to the connector contacts, or c) directly attached to the connector contacts with conductive material filling the interconnect apertures.

US Pat. No. 10,918,872

METHOD AND DEVICE FOR NEURAL IMPLANT COMMUNICATION

Saluda Medical Pty Ltd, ...

1. A method of communicating along a neural pathway, the method comprising:stimulating the neural pathway at a first location, the first location being a peripheral location, in order to evoke neural responses which propagate along the neural pathway, the neural responses being modulated with machine readable binary data;
sensing, using an implantable device, the evoked neural responses at a second location spaced apart from the first location along the neural pathway, and
demodulating, using the implantable device, the sensed neural responses to retrieve the machine readable binary data, the machine readable binary data being configured to control or alter the operation of the implanted device.

US Pat. No. 10,918,871

SYSTEMS AND METHODS FOR PERIPHERAL NERVOUS STIMULATION FOR METABOLIC AND ENDOCRINE FUNCTION

VERILY LIFE SCIENCES LLC,...

1. A method of stimulating an endocrine function of an organ of a patient by neuro stimulation, the method comprising:identifying a plurality of innervated nerves on the organ of the patient;
defining a plurality of target locations at the plurality of innervated nerves on the organ of the patient, each target location to receive placement of at least one micro particle of a plurality of micro particles, each micro particle comprising:
a power system that receives a wireless energy transmission; and
an electrode system comprising a plurality of electrodes, at least one electrode to transmit an electrical pulse to the target location;
placing each micro particle of the plurality of micro particles at a target location of the plurality of target locations;
configuring a central controller to selectively deliver power and signals wirelessly to the plurality of micro particles, the central controller comprising:
a power system to wirelessly deliver power to the plurality of micro particles;
a communication system to wirelessly communicate with the plurality of micro particles; and
a processing system to control the power system and the communication system; and
configuring at least one of the central controller or the plurality of micro particles to selectively stimulate the endocrine function of the organ by transmitting electrical pulses to the plurality of target locations using the respective electrode of each micro particle.

US Pat. No. 10,918,870

ATRIAL LEAD PLACEMENT FOR TREATMENT OF ATRIAL DYSSYNCHRONY

Medtronic, Inc., Minneap...

1. A method of positioning an atrial pacing lead for delivery of a cardiac pacing therapy, comprising:sensing electrical activity of tissue of a patient from a plurality of external electrodes;
determining a distribution of bi-atrial activation based on the sensed electrical activity during delivery of atrial pacing therapy at one or more target sites; and
determining acceptability of the atrial pacing therapy at the one or more target sites based on the distribution of bi-atrial activation.

US Pat. No. 10,918,869

METHODS AND SYSTEMS THAT MONITOR AND RESPOND TO CHANGES IN PHYSIOLOGICAL STATUS BASED ON MEASUREMENTS OF RESPIRATION CHARACTERISTICS AND PULMONARY ARTERIAL PRESSURE OBTAINED FROM IMPLANTABLE SENSORS

Pacesetter, Inc., Sylmar...

1. A method for use by a system at least a portion of which is implanted within a patient and used to deliver cardiac pacing therapy, the method comprising:using a first implantable sensor to determine a baseline measure of pulmonary arterial pressure (PAP) for the patient at rest;
using a second implantable sensor to determine a baseline measure of respiration for the patient at rest;
determining an acceptable range of PAP measures for the patient at rest based on the baseline measure of PAP that is determined for the patient at rest;
determining an acceptable range of respiration measures for the patient at rest based on the baseline measure of respiration that is determined for the patient at rest;
using the first implantable sensor to detect whenever the patient's PAP at rest is outside the acceptable range of PAP measures for the patient at rest;
using the second implantable sensor to detect whenever the patient's respiration at rest is outside the acceptable range of respiration measures for the patient at rest;
triggering a first action in response to detecting that the patient's PAP at rest is outside the acceptable range of PAP measures for the patient at rest, while contemporaneously the patient's respiration at rest is within the acceptable range of respiration measures for the patient at rest;
triggering a second action in response to detecting that the patient's respiration at rest is outside the acceptable range of respiration measures for the patient at rest, while contemporaneously the patient's PAP at rest is within the acceptable range of PAP measures for the patient at rest; and
triggering a third action in response to detecting that the patient's PAP at rest is outside the acceptable range of PAP measures for the patient at rest, while contemporaneously the patient's respiration at rest is outside the acceptable range of respiration measures for the patient at rest, the third action comprising adjusting a pacing parameter that is used for the cardiac pacing therapy and is selected from a group consisting of a pacing rate, an atrio-ventricular (AV) delay, an interatrial conduction (AA) delay, an interventricular conduction (VV) delay, an intraventricular (LV1-LV2) delay, and an LV pacing site;
wherein the first, second, and third actions differ from one another.

US Pat. No. 10,918,868

ARCHITECTURES FOR SHARING OF CURRENT SOURCES IN AN IMPLANTABLE MEDICAL DEVICE

Boston Scientific Neuromo...

1. An implantable stimulator device, comprising:a plurality of electrodes configured to provide a stimulation current to a patient;
a plurality of current sources;
a group selection matrix controllable by X group control signal lines, wherein X comprises a plural number; and
logic circuitry,
wherein the logic circuitry is configured to assert each of the at least one of the X group control signal lines at different times, wherein each of the X group control signal lines is configured when asserted to carry a group control signal to simultaneously couple the plurality of current sources to a different group of the plurality of electrodes, and
wherein the logic circuitry is further configured to program at least two of the current sources to provide a stimulation current to at least two of the electrodes of the group of the plurality of electrodes that is coupled to the plurality of current sources.

US Pat. No. 10,918,867

SYSTEMS AND METHODS FOR PRODUCING ASYNCHRONOUS NEURAL RESPONSES TO TREAT PAIN AND/OR OTHER PATIENT CONDITIONS

Nevro Corp., Redwood Cit...

1. A system for applying neural stimulation to a patient, the system comprising:a pulse generator configured to generate an electrical stimulation signal having at least a first parameter value;
an electrode array having one or more electrodes coupleable to the pulse generator,
a sensor coupleable to the pulse generator and configured to be positioned proximate an anatomical feature of the patient; and
a machine-readable medium having instructions that, when executed, cause the system to—
deliver the electrical stimulation signal to a neural population of the patient via the one or more electrodes;
sense, via the sensor, a neural response generated by the neural population in response to the electrical stimulation signal;
determine a feedback value based on the sensed neural response from the neural population; and
based on the determined feedback value, automatically adjust the first parameter value of the electrical stimulation signal to a second parameter value different than the first parameter value.

US Pat. No. 10,918,866

MEDICAL DEVICE COMMUNICATION AND CHARGING ASSEMBLIES FOR USE WITH IMPLANTABLE SIGNAL GENERATORS, AND ASSOCIATED SYSTEMS AND METHODS

Nevro Corp., Redwood Cit...

1. An implantable medical device configured for delivering electrical therapy signals to a patient's spinal region to alleviate pain, comprising:a can having a shell and a lid;
an output terminal positioned to provide electrical power to a signal delivery device;
a controller disposed within the can and coupled to the output terminal to control electrical power directed to the output terminal;
a battery disposed within the can and coupled to the controller; and
a charging and communication assembly position outside the can, including:
a support element having a first receiving surface and a second receiving surface, each of the first and second receiving surfaces extending around a corresponding perimeter of the support element;
a charging coil carried by the support element and entirely surrounding the corresponding perimeter of the first receiving surface and operably coupled to the battery via at least one first individual wire extending through the lid; and
a communication antenna carried by the support element and surrounding the corresponding perimeter of the second receiving surface and operably coupled to the controller via at least one second individual wire extending through the lid;
wherein the support element is supported in position adjacent the lid at least in part by at least one of the at least one first individual wire and the at least one second individual wire.

US Pat. No. 10,918,865

CAROTID SINUS NERVE STIMULATION

BAROLOGICS, INC., Carver...

1. A method for stimulating nerve fibers to treat a condition in a patient, the method comprising:identifying carotid sinus nerve afferent fibers in a first side of a patient's neck;
identifying cardiac-specific vagal nerve afferent fibers in the first side of the patient's neck;
placing a first multipolar electrode device around the carotid sinus nerve afferent fibers and the cardiac-specific vagal nerve afferent fibers;
stimulating the carotid sinus nerve afferent fibers and the cardiac-specific vagal nerve afferent fibers, using the first multipolar electrode device;
sensing a heart rate of the patient; and
timing the stimulation of the carotid sinus nerve afferent fibers and the cardiac-specific vagal nerve afferent fibers to the sensed heart rate, wherein timing the stimulation comprises:
delivering 25 percent of a pulse train of the stimulation at the onset of a sensed signal corresponding to a systolic phase of the patient's heartbeat; and
delivering a remaining 75 percent of the pulse train during a diastolic phase of the patient's heartbeat.

US Pat. No. 10,918,864

INTRANASAL STIMULATION FOR TREATMENT OF MEIBOMIAN GLAND DISEASE AND BLEPHARITIS

Oculeve, Inc., South San...

1. A method for treating a subject, comprising:applying or instructing the subject to apply a heat source to an eyelid of the subject prior to delivering or instructing the subject to deliver an intranasal electrical stimulation to the subject;
delivering or instructing the subject to deliver the intranasal electrical stimulation to the subject in conjunction with and after applying or instructing the subject to apply the heat source to the eyelid of the subject;
measuring or instructing the subject to measure, during the delivery of the intranasal electrical stimulation, an impedance or an electromyogram signal from a facial muscle of the subject;
providing, based on the impedance or the electromyogram signal, feedback relating to an efficacy of at least the delivered intranasal electrical stimulation;
visualizing an eyelid margin of the subject during the intranasal electrical stimulation of the subject; and
stopping or instructing the subject to stop the delivery of the intranasal electrical stimulation after observing secretion of meibum onto the eyelid margin,
wherein the subject has meibomian gland disease.

US Pat. No. 10,918,863

GENERATING ACTIVATION TIMES

Medtronic, Inc., Minneap...

1. A system for use in cardiac evaluation comprising:electrode apparatus comprising a plurality of external electrodes to be located proximate a patient's skin; and
computing apparatus comprising one or more processors, the computing apparatus coupled to the electrode apparatus and configured to:
monitor electrical activity from the patient's skin using the plurality of external electrodes over a cardiac cycle,
generate a surrogate cardiac electrical activation time based on the monitored electrical activity using baseline criterion,
determine whether to correct the surrogate cardiac electrical activation time, wherein determining whether to correct the surrogate cardiac electrical activation time comprises determining to correct the surrogate cardiac electrical activation time with late correction if the surrogate cardiac electrical activation time is greater than or equal to a selected late correction threshold, and
regenerate the surrogate cardiac electrical activation time based on the monitored electrical activity using correction criterion in response to a determination to correct the surrogate electrical activation time, wherein the correction criterion comprises at least one of early correction criterion and late correction criterion, wherein regenerating the surrogate cardiac electrical activation time based on the monitored electrical activity using correction criterion in response to a determination to correct the surrogate electrical activation time comprises regenerating the surrogate cardiac electrical activation time based on the monitored electrical activity using the late correction criterion in response to determination to correct the surrogate cardiac electrical activation time with late correction.

US Pat. No. 10,918,862

METHOD FOR AUTOMATED CLOSED-LOOP NEUROSTIMULATION FOR IMPROVING SLEEP QUALITY

HRL Laboratories, LLC, M...

1. A system for adaptable neurostimulation, the system comprising:one or more processors and a non-transitory memory having instructions encoded thereon such that when the instructions are executed, the one or more processors perform operations of:
continuous monitoring of a set of neurophysiological signals and a set of task performance metrics of a user in real-time;
continuously updating a combined physiological and behavioral model with the set of neurophysiological signals and the set of task performance metrics;
classifying the set of neurophysiological signals in real-time based on the combined physiological and behavioral model;
generating a neurostimulation intervention schedule based on the classified set of neurophysiological signals;
activating one or more electrodes via a neurostimulation intervention system to cause a timed neurostimulation intervention to be administered based on the neurostimulation intervention schedule; and
refining the neurostimulation intervention schedule and timed neurostimulation intervention based on new sets of neurophysiological signals and task performance metrics.

US Pat. No. 10,918,861

IN VIVO GENE THERAPY DELIVERY PROCEDURE AND DEVICE

Wisconsin Alumni Research...

1. A gene therapy delivery system comprising:a first balloon catheter providing a distal end having a first and second inflatable balloon spaced apart along the distal end to define an intervening catheter section and at least one passageway through a delivery lumen of the intervening catheter section for the delivery of a gene vector;
a second balloon catheter providing a distal end having a first and second inflatable balloon spaced apart along the distal end to define an intervening catheter section and at least one passageway through a delivery lumen of the intervening catheter section for the delivery of a gene vector;
a first electrode extending along the first balloon catheter;
a second electrode extending along the second balloon catheter; and
a power supply providing a voltage across the first and second balloon catheters;
wherein the first and second electrode provides a coaxial conductor having an inner and an outer coaxial conductive element and wherein the outer conductive element is removed from the coaxial conductor within the intervening catheter section to allow transmission of electrical field for electroporation.

US Pat. No. 10,918,860

BIOELECTRIC STIMULATOR

Cal-X Stars Business Acce...

1. A bioelectric stimulator programmed to produce a bioelectric signal or bioelectric signals that stimulate(s) target tissue in a subject, wherein the bioelectric signal(s) comprise(s) bioelectric signal(s) selected from the group consisting of(a) within 15%, 6 mV at 150 Hz, monophasic square wave pulse, 0.1 ms in duration, at a current of fifteen (15) mA,
(b) within 15%, 10 V/cm, pulse-width 180 ?s, 500 Hz,
(c) 3 V/cm, 10 Hz, 2 ?A, with a pulse duration of 0.2 ms,
(d) within 15%, 3 mV with a frequency of about 22 Hz, and a current of about 1 mA, followed by 3 mA,
(e) 3 mV at 2/100 Hz, alternating frequency, with current of 3 mA, followed by 15 Hz, 1 Gauss EM field, consisting of 5-mlllisecond bursts with 5-microsecond pulses followed by 200 ?s pulse duration at 30 Hz and with current amplitude of 140 mA,
(f) within 15%, alternating high-frequency (HF) and medium-frequency signals (MF), symmetric, biphasic, trapezoid pulses, with 400-?s pulse duration and 1.5/1-s ramp-up/ramp-down duration, respectively, and
(g) any combination(s) thereof.

US Pat. No. 10,918,859

RESISTIVE ELECTRIC TRANSFER BASED HIGH FREQUENCY MASSAGE DEVICE WITH SUCTION FUNCTION

SHENB CO., LTD., Seoul (...

1. A resistive electric transfer (RET)-based high-frequency massaging device with a suction function, the device comprising:a main body including an upper cover and a lower cover, wherein the upper cover has a concave curved shape, and the lower cover is coupled to the upper cover and has a suction hole defined in a bottom center thereof;
a plurality of electrode pads arranged on a bottom outer face of the lower cover circumferentially so as to be spaced apart from each other, wherein the plurality of electrode pads transmit a high frequency output onto a skin;
a high-frequency generator mounted on the lower cover and configured to apply a high frequency to the plurality of electrode pads;
a suction channel assembly communicating with the suction-hole defined in the lower cover;
a suction motor mounted on the lower cover and operatively connected to the suction channel assembly; and
a controller configured to control the high frequency applied by the high-frequency generator and suction-drive of the suction motor;
wherein the plurality of electrode pads is configured such that adjacent electrode pads have alternating polarities, and, thus, polarities for the high frequency applied from the high-frequency generator are alternated, thereby to increase heat generation efficiency resulting from fat layer stimulation of the high frequency output in a deep portion of the skin;
wherein sucking the skin via driving of the suction motor enhances skin elasticity via a massaging effect while enhancing thermal decomposition efficiency of a fat layer in a deep portion of the skin;
wherein the suction channel assembly includes:
a connection housing inserted in the suction-hole;
a filter housing inserted into the connection housing and receiving a plurality of filters; and
a guide housing for housing the connection housing and the filter housing;
wherein the connection housing includes:
a hollow connection main body for receiving the filter housing;
a suction port extending downward from a bottom center of the hollow connection main body and communicating with the hollow connection main body, wherein the suction port has a pipe shape having a smaller diameter than a diameter of the main body; and
a guide panel extending downward partially from a side wall of the hollow connection main body and being integrally formed with the connection main body, wherein the guide panel is elongated such that a lower end of the guide panel is located inside the suction-hole;
wherein, when sucking the skin through the suction-hole, fluid that has passed through the suction-hole is stored in an inner space of the guide housing, while air is supplied through the suction port to the connection main body.

US Pat. No. 10,918,858

CARDIAC VOLUME SENSING VIA AN IMPLANTABLE MEDICAL DEVICE IN SUPPORT OF CARDIAC RESYNCHRONIZATION THERAPY

CARDIAC PACEMAKERS, INC.,...

1. A method for detecting an atrial fiducial using a leadless cardiac pacemaker (LCP) that is implanted in a particular ventricle of a patient's heart, wherein the LCP has first electrode and a second electrode spaced from the first electrode with both the first electrode and the second electrode configured to be positioned in the particular ventricle of the patient's heart, the method comprising:identifying a measure of impedance between the first electrode and the second electrode of the LCP at each of a plurality of times during a cardiac cycle of the patient's heart, wherein each measure of impedance represents a measure of volume of the particular ventricle in which the LCP is implanted;
determining the atrial fiducial based on the measure of volume of the particular ventricle at two or more of the plurality of times during the cardiac cycle; and
generating a pacing pulse during the cardiac cycle, the timing of which is based at least in part on the determined atrial fiducial.

US Pat. No. 10,918,857

CONFORMAL ELECTRODE ARRAYS FOR ELECTROPHYSIOLOGIC RECORDING AND NEURAL STIMULATION WITHIN THE CEREBRAL VENTRICLES

Precision Neuroscience LL...

1. An implantable medical device for at least one of recording and stimulating a brain, the implantable medical device comprising:a flexible substrate comprising a flexible circuit;
a three-dimensional array of electrodes mounted on the flexible substrate for recording and stimulating electrical activities within ventricles of a brain, wherein:
the three-dimensional array of electrodes comprises independently controlled electrodes; and
a subset of the independently controlled electrodes can be selected for electrical interaction, wherein the independently controlled electrodes selected for electrical interaction are configured to localize electrical activity in the brain, so as to record the electrical activity; and
a foldable conformal scaffolding supporting the flexible substrate, wherein the flexible substrate is mounted to the foldable conformal scaffolding, the foldable conformal scaffolding comprising a shape memory configured to unfold the three-dimensional array of electrodes in three-dimensions when the implantable medical device is deployed within the ventricles of the brain.

US Pat. No. 10,918,856

GRAPHENE BIO-DEVICE FOR ELECTROTHERAPY

gBrain Inc., Incheon (KR...

1. A neurostimulating apparatus, consisting of:a graphene bio-device consisting of:
a flexible substrate which is PMMA (polymethylmethacrylate);
doped four-layer graphene electrodes on the flexible substrate forming an electrode array having 30 channels for recording and electrotherapy; and
an insulation layer on the doped four-layer graphene electrodes which comprise ground electrodes, reference electrodes, recording electrodes and stimulation electrodes;
a neurostimulator generating sinusoidal high frequency stimulation signals and enabling the graphen bio-device to provide neurostimulating signals to a target, wherein the sinusoidal high frequency stimulation signals include an amplitude of 1V, a frequency of 100 Hz, and a duration of 30 sec;
an amplifier intensifying brain signals from the graphene bio-device; and
an interface transmitting the amplified brain signals to a user terminal,
wherein the graphene bio-device, the neurostimulator, the amplifier, and the interface are connected to each other by a lead.

US Pat. No. 10,918,854

METHOD FOR MAKING AN ELECTROTHERAPEUTIC SOLE

1. A method for making an electrotherapeutic sole, wherein the electrotherapeutic sole comprises a main body, a plurality of electrode protuberances, and a socket; the electrode protuberances are integrally formed with the main body, protrude upward from a top portion of the main body, and correspond in position to acupoints in a human sole and vary in height so that when the human sole stamps on the top portion of the main body, tips of the electrode protuberances are pressed against an arch of the human sole and corresponding said acupoints in the human sole, the electrode protuberances including: a first plurality of electrode protuberances distributed at a first area of the top portion of the main body that corresponds to the arch of the human sole, the first plurality of electrode protuberances having different heights with depths of recesses formed between the first plurality of electrode protuberances being different, and a second plurality of electrode protuberances distributed at a second area of the top portion of the main body that corresponds to areas of the human sole that exclude the arch, each of the second plurality of electrode protuberances having a diameter smaller than that of each of the first plurality of electrode protuberances corresponding to the arch; the socket is provided in the main body; and the socket has an end electrically connected to the main body and an opposite second end formed with an insertion hole; the method comprising the steps of:mixing at least nitrile-butadiene rubber (NBR), conductive carbon black, a softening oil, a processing aid, and an accelerant thoroughly together to form a sheet, wherein the NBR is at a weight percentage of 38%˜42%; the conductive carbon black, 37%˜42%; the softening oil, 14%˜47%; the processing aid, 3%˜5%; and the accelerant, 1%˜7%;
placing the sheet in a forming space of a forming mold;
subjecting the sheet to compression molding by the forming mold at a forming temperature of 171˜189° C. for 199˜221 seconds; and
allowing the compression-molded sheet to cool, thereby completing the electrotherapeutic sole such that an electrotherapeutic pulse output terminal inserted into the insertion hole is able to send electrotherapeutic pulses generated by an electrotherapeutic pulse generator sequentially through the socket, the conductive carbon black in the electrotherapeutic sole, and the tips of the electrode protuberances to the corresponding acupoints in the human sole.

US Pat. No. 10,918,853

TOPICAL NEUROLOGICAL STIMULATION

Neurostim Solutions, LLC,...

1. A topical nerve stimulation patch comprising:a flexible substrate;
a malleable dermis conforming bottom surface of the substrate comprising adhesive surface and adapted to contact the dermis;
a flexible top outer surface of the substrate approximately parallel to the bottom surface;
a plurality of electrodes directly contacting the flexible substrate and adapted to directly contact the dermis;
a first electronic package comprising a control unit and directly contacting the flexible substrate;
a second electronic package comprising a stimulator and directly contacting the flexible substrate and configured to electrically activate the plurality of electrodes;
an antenna directly contacting the flexible substrate and configured to communicate with a remote activation device; and
a power source directly contacting the flexible substrate and in electrical communication the control unit and the stimulator;
the stimulator configured to activate in response to receipt of a communication by the antenna and to generate one or more electrical stimuli, the communication generated by a remote control device in wireless communication with the electronic circuitry, the remote control device configured to provide a signal to start stimulation on a user via the electrodes, the signal generated in response to one of: the user interacting with the remote control device or an event detected by a sensor; and
the electrical stimuli configured to stimulate one or more nerves of the user wearing the topical nerve stimulation patch at least at one location proximate to the patch.

US Pat. No. 10,918,852

NEURO-STEM CELL STIMULATION AND GROWTH ENHANCEMENT WITH IMPLANTABLE NANODEVICE

INTERNATIONAL BUSINESS MA...

1. A nanodevice, comprising:an electropolymerized electrical conductor formed over tops of nanorods to form a reservoir between the electropolymerized electrical conductor and a substrate, the electropolymerized electrical conductor including pores that open and close responsively to electrical signals applied to the nanorods;
a cell loading region configured to receive cells; and
a neurotrophic dispensing material loaded in the reservoir, the neurotrophic dispensing material being dispersed when the pores are open to affect growth of the cells when in vivo.

US Pat. No. 10,918,851

VALVE CONNECTOR FOR MEDICAL LINES

INDUSTRIE BORLA S.P.A., ...

1. Valve connector for medical lines, comprising:a tubular body having an inlet end designed for the engagement of a fluid introducer and an outlet end,
a hollow spike arranged axially within the cavity of the tubular body and having a closed tip facing said inlet end of the tubular body and axially spaced therefrom, said hollow spike being in communication with said outlet end,
a sealing member formed by an elastic hollow element interposed between said tubular body and said hollow spike and having an elastic head provided with a pre-slit and normally arranged in a closure condition in said inlet end of the tubular body, wherein said pre-slit is closed;
said elastic head being axially moveable against said closed tip of the hollow spike for interacting with said closed tip so as to take an elastically deformed condition of opening of said pre-slit, and
said elastic hollow element further comprising a base part radially spaced from said hollow spike so as to define therewith an annular chamber,
said base part of the elastic hollow element having a generally barrel-like shape with a wall having a differentiated radial thickness and formed externally with thickened axial lobes,
each lobe of said axial lobes having a radial thickness progressively decreasing towards axial areas having minimum thicknesses of said wall,
said axial lobes arranged circumferentially adjacent to each other on said base part, and each axial area of said axial areas having minimum thicknesses located circumferentially between a plurality of said axial lobes,
said elastic hollow element comprising a first cylindrical portion and said hollow spike comprising a second cylindrical portion,
said elastic hollow element elastically deformable in response to an insertion of the fluid introducer into the inlet end such that said axial lobes bend in the annular chamber to fasten the first cylindrical portion against the second cylindrical portion.

US Pat. No. 10,918,850

BLOCKING AND/OR RESTRICTING VALVE AND BLOOD TREATMENT DEVICE COMPRISING SUCH A VALVE

FRESENIUS MEDICAL CARE DE...

1. A valve having a pneumatic actuator and a valve housing which has a fluid system having a fluid inlet, a fluid outlet, and a fluid chamber arranged therebetween, wherein the fluid chamber comprises a blocking geometry and is bounded by a barrier membrane with respect to the blocking geometry, characterized in that the barrier membrane is connected to a tappet on its side remote from the fluid chamber such that it is pressed toward the blocking geometry and can be lifted by it by a movement of the tappet, with the tappet being arranged in a freely floating manner in a hollow space of the valve housing, characterized in that a mechanical spring is arranged between the tappet and the valve housing, the spring pre-loading the tappet against the valve housing such that it presses the barrier membrane toward the blocking geometry in its zero position, and characterized in that the pneumatic actuator comprises an inflatable hose radially surrounding the tappet, acts on the tappet, and is configured such that it can move the tappet out of the zero position against the pre-load of the mechanical spring and can thus release the barrier membrane from the blocking geometry.

US Pat. No. 10,918,849

CONNECTION APPARATUS FOR A MEDICAL DEVICE

Becton Dickinson and Comp...

1. A connection apparatus for a medical device comprising:a first connection member having a first end and a second end, the first connection member defining at least one channel adjacent the first end, the at least one channel having a first portion extending in an axial direction, the at least one channel having a shoulder adjacent to the first end of the first connection member that defines a channel entry, the at least one channel having a second portion extending in a transverse direction relative to the axial direction and defining a terminus; and
a second connection member having a first end and a second end, the first end defining an interior cavity having at least one protrusion therein,
wherein when the at least one protrusion of the second connection member enters the at least one channel of the first connection member, axial movement of the second connection member towards the first connection member causes engagement of the at least one protrusion with the first connection member and at least one of the first and second connection members to rotate relative to the other connection member to enter a locked state where the at least one protrusion reaches the terminus of the second portion of the at least one channel, wherein the shoulder is configured to guide the at least one protrusion of the second connection member into the channel entry regardless of the orientation of the at least one protrusion relative to the channel entry, and
wherein the connection apparatus further comprises a visual indicator of the locked state between the first connection member and the second connection member.

US Pat. No. 10,918,848

HIGH FLOW ENTERNAL CONNECTOR SYSTEM

1. A two part threadably engageable and disengageable ISO 80369-3 medical connector system not mating with I.V. luers for preventing any interlocking or threadable fit with an ISO ANSI 1986 Standard luer dimensioned syringe tip or connector comprising:a first part ISO 80369-3 dimensionally compliant enteral fluid delivery side connector capable of delivering pressurized enteral fluid by enteral pump or syringe and a mating second part structurally modified ISO 80369-3 compatible enteral fluid receiving side connector;
said second part fluid receiving side connector structurally modified to include an outer housing having an internal thread engagement and disengagement element with a thread depth length and a bottom end where an internal fluid passageway is located, and a resilient internal circular sealing surface area “O” ring insertably pressed fit into the bottom end of the thread depth length to capture and retain said “O” ring within said outer housing below the internal thread engagement and disengagement element;
wherein said internal thread engagement and disengagement element has an internal diameter that is less than the diameter of said “O” ring, thereby preventing the “O” ring from falling out of the bottom end of the housing when disengaged from a syringe tie;
said resilient internal circular sealing surface area “O” ring forming and maintaining a fluid tight compressive contact sealing engagement with the first part fluid delivery side connector when said first part fluid delivery side connector is fully threadably engaged with the second part fluid receiving side connector, and the resilient internal circular sealing surface area “O” ring maintaining the fluid tight compressive contact sealing engagement when the first part fluid delivery side connector delivers pressurized enteral fluid by enteral pump or syringe.

US Pat. No. 10,918,847

IMPLANTABLE INTERFACE DEVICE

Gil Stynes, Geelong (AU)...

1. An interface device for implantation in a subject, the device including:a. a tissue integration layer having a porous structure forming a scaffold into which tissue integrates to anchor the device when implanted;
b. a crowning element attached to an upper surface of the tissue integration layer and configured such that once implanted, there is epidermal attachment to part of the crowning element, and part of the crowning element extends through the epidermis and is accessible from outside the subject's body;
c. a seal capable of applying negative pressure overlaying the part of the crowning element accessible from outside the subject's body; and
d. a source of negative pressure;
wherein the porous structure of the tissue integration layer is interconnected for tissue ingress during implantation; and
wherein the tissue integration layer is sized and shaped to provide a foundation that supports the crowning element such that when implanted, the tissue integration layer is entirely anchored beneath the epidermis.

US Pat. No. 10,918,846

IMPACTING TYPE APPLICATOR FOR MICRONEEDLE PATCH AND LEADING END MEMBER

Labo Juversa Co., Ltd., ...

1. An impacting type applicator that applies a microneedle patch to a skin by pressing the microneedle patch against the skin, comprising:a main body;
an actuator that is movably attached to the main body, and that has a leading end for attaching to the microneedle patch;
a resilient body that imparts a biasing force to the actuator;
a lock mechanism that locks the actuator in a state where the resilient body exerts the biasing force on the main body; and
a releasing member that releases the lock mechanism, and
a biasing force imparting mechanism that imparts a further biasing force to the actuator in a state where the actuator is moved toward a leading end part of the main body and thereby presses the microneedle patch against the skin.

US Pat. No. 10,918,845

TRANSDERMAL ADMINISTRATION DEVICE

TOPPAN PRINTING CO., LTD....

1. A transdermal administration device, comprising:an adhesive sheet comprising a first adhesive sheet portion and a second adhesive sheet portion;
a first administration member adhered on a surface of the first adhesive sheet portion and comprising a first substrate and a plurality of first projections protruding from a first administration surface of the first substrate; and
a second administration member adhered on a surface of the second adhesive sheet portion and comprising a second substrate and a plurality of second projections protruding from a second administration surface of the second substrate,
wherein the adhesive sheet is formed such that the first adhesive sheet portion is an outer adhesive sheet having an annular shape with an opening and that the second adhesive sheet portion is an inner adhesive sheet positioned inside the opening of the outer adhesive sheet and separates from the first adhesive sheet portion, the first administration member has an aperture, and the second substrate is positioned on the surface of the second adhesive sheet portion such that the second administration member is positioned within the aperture of the first administration member, the plurality of second projections in the second administration member is arrayed in a rectangular matrix, and the plurality of first projections in the first administration member is arrayed radially.

US Pat. No. 10,918,844

NEEDLE-LIKE STRUCTURE AND METHOD FOR MANUFACTURING THE SAME

Toppan Printing Co., Ltd....

1. A needle-like structure, comprising:a substrate having an X direction and a Y direction perpendicular to the X direction;
a plurality of projections formed in parallel rows on the substrate and extended in the Y direction; and
a plurality of needle portions formed on each of the projections such that each of the needle portions has a side line extending from a top surface of a respective one of the projections in a cross section of the X direction and forming an angle ?1 of less than 90° with respect to the top surface of the respective one of the projections in the cross section of the X direction,
wherein each of the projections has the plurality of needle portions formed in a row and a side line extending from a top surface of the substrate in the cross section of the X direction and forming an angle ?2 of less than 90° with respect to the top surface of the substrate in the cross section of the X direction, a tip of each of the needle portions extends in a height direction of the projections, the needle portions are spaced part from one another along the direction in which each of the projections is extended, and the projections and needle portions are formed such that each of the needle portions has a height h1 in a range of from 100 ?m to 2,000 ?m and that each of the projections has a height h2 which is not less than 0.2×H and not more than 0.8 H, where H is a sum of the height h2 and the height h1 of each needle portion.

US Pat. No. 10,918,843

WOUND CARE AND INFUSION METHOD AND SYSTEM UTILIZING A THERMALLY-TREATED THERAPEUTIC AGENT

THERMOTEK, INC., Flower ...

1. A wound-care system, comprising:a patch;
an infusion tube coupled to the patch;
an oxygen concentrator coupled to the patch via the infusion tube;
a vacuum tube coupled to the patch;
a pump coupled to the patch via the vacuum tube;
a reservoir containing a therapeutic agent, the reservoir being fluidly coupled to the infusion tube;
a temperature control fluidly coupled to the reservoir, the temperature control adjusting a temperature of the therapeutic agent;
an oxygen solenoid disposed in the infusion tube between the oxygen concentrator and the patch;
a patch solenoid disposed in the vacuum tube between the patch and the pump; and
wherein closing the oxygen solenoid and the patch solenoid facilitates pressure testing of the patch.

US Pat. No. 10,918,842

BALLOON CATHETER

TERUMO KABUSHIKI KAISHA, ...

1. A balloon catheter comprising:a first shaft that includes a first lumen enabling a pressurizing medium to circulate therethrough, and that extends in an axial direction;
a first balloon disposed on a distal side of the first shaft, the first balloon being deformable in a radially expandable manner in response to supply of the pressurizing medium to the first balloon via the first lumen and being deformable in a radially contractible manner in response to discharge of the pressurizing medium from the first balloon via the first lumen;
a second shaft that includes a second lumen enabling the pressurizing medium to circulate therethrough, and that extends in the axial direction;
a second balloon disposed on a distal side of the second shaft and covering an outer periphery of the first balloon, the second balloon being deformable in a radially expandable manner in response to supply of the pressurizing medium to the second balloon via the second lumen and being deformable in a radially contractible manner in response to discharge of the pressurizing medium via the second lumen;
the first shaft being movable in the axial direction relative to the second shaft;
the first balloon being movable in the axial direction relative to the second balloon in response to movement of the first shaft, and
the second balloon comprises an inner layer and an outer layer, the inner layer possessing an outer periphery and covering the outer periphery of the first balloon, the outer layer covering the outer periphery of the inner layer, and a space between the inner layer and the outer layer that communicates with the second lumen.

US Pat. No. 10,918,841

ABSCESS DRAINAGE

MAR-MED CO., Grand Rapid...

1. A drainage device for holding an incision in an abscess of a subject open to allow drainage of fluid out of the abscess, the drainage device comprising an elongate body, a first extension member extending laterally from the elongate body and disposed at a first longitudinal end of the elongate body, and a second extension member extending laterally from the elongate body and disposed at a second longitudinal end of the elongate body, the first and second extension members extending from the elongate body to respective free ends of the extension members along a linear plane, wherein the first and second extension members are disposed at the respective first and second longitudinal ends such that an entire length of the elongate body extends between the first and second extension members, the length of the elongate body being longer than lengths of the first and second extension members, the elongate body being configured for insertion into the abscess, and the first and second extension members being configured to retain at least a portion of the elongate body in the abscess, the elongate body facilitating drainage of fluid out of the abscess, wherein the elongate body is free of a passage extending through an interior of the elongate body such that in use a portion of the device is disposed within the abscess and a portion of the device is disposed outside of the abscess and outside of the subject whereby the drainage of fluid flows around the elongate body when the drainage device is inserted into the abscess, wherein the elongate body and extension members are formed entirely from silicone.

US Pat. No. 10,918,840

DRUG DEVICE ELECTROPORATION SYSTEM

Hydra Vascular LLC, Scot...

1. A balloon catheter comprising:an elastic conducting alloy cage;
a balloon that is encased within the elastic conducting alloy cage, wherein the elastic alloy cage is biased to be in a collapsed state on the balloon and is expandable by expansion of the balloon, and a working length of the balloon is coated with a coating including a therapeutic bio-active agent and an excipient; and
a shaft having an electrode to provide a single polarity from an electrical power source to the elastic conducting alloy cage, wherein the elastic conducting alloy cage is to apply energy to a target tissue and emit an electric field to facilitate concurrent transfer of the bio-active agent from the coating on the working length of the balloon to the target tissue.

US Pat. No. 10,918,839

BALLOON CATHETER

Jaro Mayda, II, Lewisvil...

1. A fluid delivery device, comprising:a spike including a base end and a pointed end, an inlet opening located along the shaft of the spike between the base end and the pointed end, and an outlet opening located on the pointed end;
an inner flexible layer, wherein the base end of the spike is attached to the inner flexible layer; and
an outer flexible layer, wherein the spike punctures the outer flexible layer in response to the inner flexible layer moving towards the outer flexible layer in response to inflation of a volume of space enclosed by the inner flexible layer, wherein the outer flexible layer is blister casing and the inner flexible layer is a balloon casing.

US Pat. No. 10,918,838

DEVICE FOR CONTROLLING BLEEDING FROM A BALLISTIC PENETRATING OR PERFORATING WOUND

1. An emergency tamponade catheter for controlling bleeding from a penetrating or perforating wound in a patient prior to reach a site for definitive care such as the operating room and the like, the penetrating or perforating wound having a curved or irregular shaped wound track, comprising:a catheter extending from a proximal end and a distal end and having an inner catheter lumen;
a bulbousor enlarged rounded exploring tip located on said distal end of said catheter for facilitating non-damaging insertion into the curved or irregular shaped wound of the patient;
a non-elastic inflatable balloon secured to said catheter with said non-elastic inflatable balloon being in fluid communication with said inner catheter lumen of said catheter;
a removable outer sheath overlaying said inflatable balloon for maintaining said inflatable balloon in a non-inflated condition to insert said inflatable balloon within the curved or irregular shaped wound of the patient;
said removable outer sheath mating with said bulbousor enlarged rounded exploring tip to provide a smooth junction between said exploring tip and said removable outer sheath,
a bendable flexible stiffening stylet receivable within said inner catheter lumen of said catheter;
said bendable flexible stiffening stylet having a proximal end defining an external stylet handle;
said bendable flexible stiffening stylet being pre-bent to aid in navigating said catheter into the curved or irregular shaped wound of the patient;
said removable sheath maintaining said catheter in a straight condition against the prebend of said bendable flexible stiffening stylet for facilitating initial insertion into the curved or irregular shaped wound; a perforation in said removable outer sheath;
a perforation in said removable outer sheath for partially retracting said removable outer sheath and enabling said pre-bend of said bendable flexible stiffening stylet to produce a curved configuration in proximity to said rounded exploring tip to assist in finding the true curved or irregular shaped wound track;
said removable outer sheath and said stylet being removable for inflating said inflatable balloon by an introduction of a fluid through said inner catheter lumen of said catheter for enabling said inflated nonelastic inflatable balloon to create pressure within the wound of the patient to control bleeding from the curved or irregular shaped wound;
said non-elastic inflatable balloon being deflatable for removing the emergency tamponade catheter from the curved or irregular shaped wound upon reaching a site for definitive care such as the operating room and the like;
and a fitting coupled to said proximal end of said catheter for receiving a pump for inflating said non-elastic inflatable balloon.

US Pat. No. 10,918,837

SAFETY NEEDLE ASSEMBLIES AND RELATED METHODS

B. Braun Melsungen AG, M...

1. A safety catheter assembly comprising:a catheter hub comprising an interior cavity;
a valve and a valve opener having a nose section sized and shaped for pushing into the valve to open one or more slits of the valve, said valve and said valve opener being located in the interior cavity of the catheter hub;
a catheter tube attached to the catheter hub;
a needle hub;
a needle attached to the needle hub and projecting through the catheter tube and having a needle tip extending out of a distal end of the catheter tube in a ready to use position;
a needle guard positioned in the interior cavity of the catheter hub;
wherein the needle guard comprises a proximal wall having an opening and two arms each comprising an end;
wherein a support is formed with the valve opener and wherein the two ends of the two arms on the needle guard rest on surfaces of the support; and
wherein the support spaces the two ends of the two arms of the needle guard from the needle in the ready to use position so as to reduce drag between the needle and the needle guard when the needle retracts from the catheter tube and the catheter hub following vascular access.

US Pat. No. 10,918,836

CATHETER PROTECTOR

Concept H2-ITEX Inc., Br...

1. A protective cover for a body member of a patient having a catheter inserted therein at a catheter insertion point, the protective cover comprising a sleeve configured to wrap around the body member over the catheter, the sleeve comprising:a sleeve body configured for covering a surface of the body member of the patient including a joint, the sleeve body being made of a material that is non-rigid, flexible and elastic, the sleeve body conforming to the surface of the body member of the patient that is covered;
an openable window for covering and providing access to the catheter when the protective cover is worn, the openable window being openable with respect to the sleeve body and defining an openable contour portion being fastenable to the sleeve body by a waterproof fastener along the openable contour portion which is waterproof along a whole length thereof, the openable window defining an inner surface and comprising an area on the inner surface for securing an antiseptic agent, wherein the inner surface of the openable window is applied onto the catheter insertion point when the openable window is closed, wherein the inner surface is brought away from the catheter insertion point when the openable window is opened,
a proximal band and a distal band to be provided around the body member at a proximal end and a distal end of the sleeve body, respectively, each of the proximal band and the distal band being inflatable to press against the body member and provide waterproofness to the proximal end and to the distal end of the sleeve body, and
wherein the protective cover is free of any rigid member covering the body member.

US Pat. No. 10,918,835

DELIVERY SYSTEM FOR ACTIVE AGENT COATED BALLOON

Surmodics, Inc., Eden Pr...

1. A delivery system for introducing an active agent coated balloon into a subject comprising:a tunneling sheath comprising
a tubular shaft having an outer diameter and defining a lumen, the tubular shaft having a proximal end and a distal end;
a proximal collar defining a lumen, the proximal collar attached to the tubular shaft at the proximal end, the proximal collar comprising an outer diameter that is greater than the outer diameter of the tubular shaft; and
a balloon catheter comprising
a balloon catheter shaft disposed within the tubular shaft, the balloon catheter shaft comprising a lumen for the passage of a fluid therein;
an expandable balloon disposed on the balloon catheter shaft in fluid communication with the lumen of the balloon catheter shaft; and
an active agent layer disposed on the expandable balloon;
an introducing sheath disposed about the tunneling sheath;
wherein the position of the expandable balloon is configured to be stationary relative to the tubular shaft with the proximal collar of the tunneling sheath fastened onto the balloon catheter as the delivery system is passed through a blood vessel of a patient;
wherein the expandable balloon is configured be passed at least part way out of the tubular shaft after the proximal collar of the tunneling sheath is unfastened from the balloon catheter; and
wherein a volume of the tubular shaft that is not taken up by the balloon catheter is filled with a liquid as the expandable balloon is passed at least part way out of the tubular shaft.

US Pat. No. 10,918,834

ROTATIONALLY TORQUABLE ENDOVASCULAR DEVICE WITH ACTUATABLE WORKING END

RAPID MEDICAL LTD., Yokn...

1. An endovascular device, comprising:a hollow shaft having a proximal end and a distal end, the hollow shaft being sized for insertion into a blood vessel;
a control line having a proximal end and a distal end, the control line configured to extend through the hollow shaft;
an actuatable working portion situated distally from the distal end of the hollow shaft, the actuatable working portion configured to receive an actuation force transmitted via the distal end of the control line;
an actuator configured to exert the actuation force on the proximal end of the control line to thereby cause relative movement between the control line and the hollow shaft and to actuate the actuatable working portion;
at least one control line rotation restrictor integral with the control line and configured to be located at least partially within the hollow shaft; and
at least one rotation restriction barrier associated with at least one of the hollow shaft or the actuatable working portion, wherein the at least one rotation restriction barrier is configured to engage with the at least one control line rotation restrictor to substantially impede the control line from rotating relative to the actuatable working portion, while permitting relative axial movement between the control line and the hollow shaft.

US Pat. No. 10,918,833

MODULAR HANDLE ASSEMBLY FOR A STEERABLE CATHETER

FREUDENBERG MEDICAL, LLC,...

1. A modular handle assembly comprising:a steerable catheter having at least one deflection wire;
a handle extending along a longitudinal axis for being positioned about a portion of the steerable catheter;
a dial rotatably connected to said handle and rotatable about a first rotary axis extending transverse to said longitudinal axis;
a first gear arm extending radially relative to said first rotational axis from said dial and terminating at a first gear tip presenting a first friction surface;
a second gear arm rotatably connected to said handle and rotatable about a second rotary axis extending in spaced and parallel relationship with said first rotary axis;
said second gear arm extending radially relative to said second rotary axis and terminating at a second gear tip presenting a second friction surface disposed against said first friction surface such that rotation of said dial in a first rotary direction about said first rotary axis effectuates rotation of said second gear arm in an opposite direction about said second rotary axis; and
a cam coupled with at least one said first and second gear tips for providing movement of said cam during rotation of said dial, said cam presenting at least one deflection surface for deflecting said at least one deflection wire extending across said at least one deflection surface during rotation of said dial to steer a distal end of said steerable catheter with said first and second gear tips.

US Pat. No. 10,918,832

CATHETER WITH IMPROVED LOOP CONTRACTION AND GREATER CONTRACTION DISPLACEMENT

BIOSENSE WEBSTER (ISRAEL)...

1. An electrophysiology catheter comprising:an elongated catheter body;
a contraction wire; and
a distal assembly configured for contraction by actuation of the contraction wire, the distal assembly having a shape-memory support member having a 3-D configuration, the distal assembly including a radially-constrictive tubing surrounding the shape-memory support member and a coextensive portion of the contraction wire,
in which the radially constrictive tubing includes manufactured fibers formed from a liquid crystal polymer, and
in which the shape-memory support member includes:
a proximal generally rectangular portion comprising a first flat side having a first height and a first rounded side having a first width,
an intermediate generally rectangular portion distal of the proximal generally rectangular portion comprising a second flat side having a second height that is greater than the first height and a second rounded side having a width that is less than the first width,
a distal generally rectangular portion distal of the intermediate generally rectangular portion comprising a third flat side having a third height that is greater than the second height and a third rounded side having a third width that is less than the second width, and
a distal end distal of the distal generally rectangular portion having a round cross section.

US Pat. No. 10,918,831

PRESSURE CATHETER AND CONNECTOR DEVICE

Laborie Medical Technolog...

1. A connector apparatus for a pressure sensing catheter, the pressure sensing catheter comprising one or more hollow pressure compliant members, comprising:a first complementary connector in fluid communication with the one or more hollow pressure compliant members, the first complementary connector having an aligning portion and a charging portion along a central axis of the first complementary connector with a resilient member located between the aligning portion and the charging portion, the aligning portion having a cross-sectional area, normal to the central axis, and less than a cross-sectional area normal to the central axis of the charging portion;
a second complementary connector having a proximal coupler with an alignment section and a charging section along a central axis thereof, the alignment section having a cross-sectional area complementary to the cross-sectional area of the aligning portion to receive the aligning portion therein, the charging section having a cross-sectional area complementary to receive the charging portion and the resilient member therein and form a fluid tight seal therebetween,
the first complementary connector being configured to displace a predetermined volume of fluid, from within the proximal coupler into the one or more hollow pressure compliant members when the alignment section receives the aligning portion, the charging section receives the charging portion, and the resilient member forms the fluid tight seal within the charging section; and
a pressure detection device fluidly coupled to the one or more hollow pressure compliant members so as to detect a pressure associated with the one or more hollow pressure compliant members
wherein the proximal coupler comprises an engagement section, the engagement section having a cross-sectional area complementary to an engagement portion of the first complementary connector and one of the engagement portion and the engagement section has a protrusion; and
the other of the engagement portion and the engagement section has a front surface leading to a complementary recess for frictionally receiving the protrusion after the front surface has engaged the protrusion, the front surface forming a reduction in the cross-sectional area of the other of the engagement portion and the engagement section leading to the complementary recess such that the protrusion encounters the reduction in the cross-sectional area prior to encountering the complementary recess, the recess enclosing the protrusion within the other of the engagement portion and the engagement section, the protrusion and recess forming a snap fit to frictionally engage and retain the first complementary connector within the second complementary connector when the protrusion and recess are aligned.

US Pat. No. 10,918,830

BOOSTING CATHETER AND RELATED SYSTEMS AND METHODS

QXMedical, LLC, Rosevill...

1. A boosting catheter comprising:(a) a distal tube comprising a tubular wall and a tube lumen defined within the distal tube by the tubular wall; and
(b) a proximal shaft operably coupled to a proximal portion of the distal tube, the proximal shaft comprising:
(i) a shaft lumen defined in the proximal shaft;
(ii) at least one elongate member disposed within the shaft lumen;
(iii) a visual marker associated with at least one of the at least one elongate member; and
(iv) a distal opening in fluid communication with the shaft lumen, whereby the shaft lumen is in fluid communication with the tube lumen,
wherein the proximal shaft is configured to extend distally into a portion of the tube lumen such that the shaft lumen extends distally past a proximal end of the distal tube, and
wherein the proximal shaft is configured to extend distally into a portion of the tubular wall such that the shaft lumen extends distally into the tubular wall and such that the distal opening is in fluid communication with the tube lumen.

US Pat. No. 10,918,829

FULLY COMPLIANT LARGE BORE EXPANDABLE SHEATH

Boston Scientific Scimed,...

1. An expandable sheath, comprising:a compliant membrane having a lumen extending therethrough; and
an entire discontinuous outer member permanently attached to the compliant membrane;
wherein more than one portion of the discontinuous outer member extends continuously around a circumference of the compliant membrane in a first configuration
wherein the discontinuous outer member includes more than one longitudinal line consisting of a plurality of weakening features;
wherein the discontinuous outer member is configured to tear along at least a portion of more than one longitudinal line of the plurality of weakening features to form a second configuration when subjected to a radially outward force from within the compliant membrane,
wherein at least a portion of the plurality of weakening features is disposed directly over one or more folds of the compliant membrane, and
wherein the more than one longitudinal line of the plurality of weakening features alternate circumferentially with longitudinal lines free of weakening features in an at least partially torn second configuration.

US Pat. No. 10,918,828

KINK AND COMPRESSION TOLERANT MEDICAL TUBING

Fresenius Medical Care Ho...

1. A medical tubing system, comprising:a medical tube defining a central longitudinal axis and including internal ribs extending inwardly from an inner wall of the tube toward the central longitudinal axis, an outer wall of the tube defining grooves in radial alignment with the internal ribs and extending longitudinally along the tube; and
a tube closure device comprising:
a sleeve defining an opening that slidingly receives the tube, the sleeve including an externally threaded portion;
a set of jaws comprising three jaws that are each connected to and extending longitudinally from the externally threaded portion of the sleeve, each of the jaws including a ramp surface extending along an acute angle relative to the central longitudinal axis, and each of the jaws being radially deflectable in relation to the externally threaded portion of the sleeve; and
a clamp collar positioned around at least portions of set of jaws, the clamp collar including an internally threaded portion that is threadedly coupled with the externally threaded portion of the sleeve, the clamp collar including an annular ramp surface that corresponds to and slidingly mates against the ramp surface of each of the jaws, the annular ramp surface extending from the internally threaded portion and defining an end opening of the clamp collar that is larger in diameter than the internally threaded portion.

US Pat. No. 10,918,827

CATHETER DEVICE AND METHOD FOR INDUCING NEGATIVE PRESSURE IN A PATIENT'S BLADDER

Strataca Systems Limited

1. A ureteral catheter configured to be deployed in a urinary tract of a patient, comprising:an elongated tube comprising a proximal portion configured for placement in a ureter of the patient, a distal portion comprising a distal end, and a sidewall extending between a proximal end and the distal end of the elongated tube defining at least one drainage lumen extending through the tube, the sidewall comprising a drainage portion which allows fluid to pass through the sidewall and into the drainage lumen; and
a permeable tissue support directly or indirectly connected to the distal portion of the elongated tube and extending axially and/or radially therefrom, the tissue support being configured to be deployed in the urinary tract to maintain the distal end of the elongated tube at a predetermined position in a ureter, a renal pelvis, or a kidney of the patient,
wherein, when deployed, the permeable tissue support defines a three-dimensional shape of sufficient size to permit flow of at least a portion of fluid from the urinary tract through the tissue support and drainage portion of the elongated tube to the at least one drainage lumen upon application of negative pressure through the catheter, and wherein a diameter of the three-dimensional shape at a distal end of the permeable tissue support is greater than a diameter of the three dimensional shape at a proximal end of the permeable tissue support at the distal end of the elongated tube.

US Pat. No. 10,918,826

COAXIAL VENAL CANNULA

Nordson Corporation, Wes...

1. A method of making a cannula assembly, the method comprising:forming an elongate flexible infusion tube having a proximal end and a distal end;
forming an elongate flexible drainage tube having a proximal end and a distal end;
forming a connector having a return opening and a connector aperture;
inserting said elongate infusion tube into said return opening and out said connector aperture such that a portion of said infusion tube extends through said connector, wherein said portion of said infusion tube extending through said connector gradually tapers across said connector;
attaching said infusion tube to said return opening of said connector;
connecting said distal end of said elongate drainage tube to a mid-portion of said elongate infusion tube;
installing a drainage site having at least one drainage aperture at said distal end of said elongate drainage tube; and
installing an infusion site having at least one infusion aperture at said distal end of said elongate infusion tube.

US Pat. No. 10,918,825

URETERAL AND BLADDER CATHETERS AND METHODS OF INDUCING NEGATIVE PRESSURE TO INCREASE RENAL PERFUSION

Strataca Systems Limited

1. A ureteral catheter, comprising:(a) a proximal portion; and
(b) a distal portion, the distal portion comprising a retention portion, wherein the retention portion comprises an inwardly facing side comprising one or more drainage ports and an outwardly facing side which is essentially free or free of drainage ports, and wherein, when negative pressure is applied through the ureteral catheter, fluid is drawn into the ureteral catheter through the one or more drainage ports while mucosal tissue is prevented from appreciably occluding the one or more drainage ports by contact with the outwardly facing side of the retention portion.

US Pat. No. 10,918,824

APPARATUS FOR STIMULATING NEURAL ACTIVITY

SYMBOLICS INC., Lincoln,...

1. An apparatus for stimulating neural activity in the brain of a user of a smartphone, comprising:a smartphone with a display screen and that is capable of running apps, wherein the display screen is a touch-screen display;
a processor in the smartphone that causes at least one portion of the display screen to flicker in a controlled manner, wherein the display flickers at a color temperature in a range of 4000° K ±10%, exposing the user of the smartphone to the flicker during an exposure time thereby producing an effect on the brain of the user, wherein the at least one portion is in the middle of the display, around edges of the display, is the entire display or is a background on the display; and
an app running on the smartphone that adjusts the flicker based upon the age of the user.

US Pat. No. 10,918,823

DISPLAY CONTROL METHOD AND DEVICE

BOE TECHNOLOGY GROUP CO.,...

1. A display control method, comprising:acquiring current data of a user, the current data comprising identity information of the user and current time;
determining contents to be played according to the current data and feature parameters of video contents in a video database, wherein the video contents comprise audio information and video information;
generating a lulling instruction;
acquiring behavior feature data of the user according to the lulling instruction, and determining a current stage of a sleep process that the user is in according to the behavior feature data; wherein the sleep process comprises a waking stage, a first sleepy stage, a second sleepy stage, a pre-sleep stage, a shallow sleep stage, and a deep sleep stage arranged sequentially; and
acquiring control instructions matched with the current stage and subsequent stages of the current stage of the sleep process that the user is in respectively, and executing corresponding operations on the contents to be played according to the control instructions.

US Pat. No. 10,918,822

HUMIDIFIER FOR BREATHING GAS HEATING AND HUMIDIFICATION SYSTEM

VAPOTHERM, INC., Exeter,...

1. A humidification system for increasing residence time of a breathing gas within a humidification chamber so as to provide heated and humidified breathing gas to a patient through a nasal cannula, the system comprising:a humidification canister having:
a heat conducting base,
a liquid reservoir configured to hold a liquid,
a humidification chamber having a curved inner wall positioned within the liquid reservoir,
a gas inflow conduit configured to convey a flow of breathing gas into the humidification chamber,
a gas outflow conduit configured to convey breathing gas away from the humidification chamber after being humidified within the chamber, and
a first baffle tube having an inlet section and a discharge section, the inlet section interfacing with the gas inflow conduit so as to receive the flow of breathing gas in a first generally horizontal direction of flow and direct the received flow of breathing gas in a second, generally vertical direction of flow, the discharge section having an outlet baffle and being positioned so as to re-direct the gas from the vertical direction of flow to a generally downward direction of flow when discharging from the outlet baffle into the humidification chamber; and
a base unit comprising:
a housing,
a fluid heater disposed on a surface of the housing and configured to transfer heat to the heat conducting base of the humidification canister,
a blower enclosed within the housing and configured to provide the flow of breathing gas through the gas inflow conduit, and
a receptacle configured to releasably couple the humidification canister to the base unit, the receptacle sized and shaped to accommodate the humidification canister;
wherein the receptacle is configured to position the humidification canister above the fluid heater and to align the gas inflow conduit with the base unit to provide breathing gas to the humidification chamber.

US Pat. No. 10,918,821

BREATHING ASSISTANCE APPARATUS

14. A method comprising:supplying a flow of gases from a gases supply;
heating a humidifier with a chamber heater;
as performed by a controller comprising a processor and memory:
monitoring for a breathing pattern,
in response to no breathing pattern detected for a first predetermined time period:
switching off power to said chamber heater,
controlling the gases supply to set said flow of gases from said gases supply for a second predetermined time, and
after said second predetermined time, switching off said gases supply; and
heating said flow of gases for at least a portion of said second predetermined time using a heater separate from said chamber heater.

US Pat. No. 10,918,820

INHALER COMPONENT

Batmark Limited, London ...

10. An inhaler comprising:an inhaler component and a reusable inhaler part, wherein the inhaler component includes:
a heating element configured to evaporate a portion of a liquid material;
a liquid container for retaining the liquid material, the liquid container comprising a valve which is openable upon coupling of the inhaler component to the inhaler, the opening of the valve allowing the liquid material to be released from the liquid container;
a wick configured to automatically supply the liquid material to the heating element; and
a gap configured to automatically supply the wick with the liquid material; and
wherein the reusable inhaler part includes:
a pin configured to open the valve of the liquid container.

US Pat. No. 10,918,819

CANNULA FOR MINIMIZING DILUTION OF DOSING DURING NITRIC OXIDE DELIVERY

Mallinckrodt Hospital Pro...

15. A method of administering nitric oxide to a patient, the method comprising:administering a plurality of pulses of a gas comprising nitric oxide to the patient, wherein the plurality of pulses are administered through a nasal cannula comprising a cannula nosepiece comprising a nitric oxide flow path having a volume that is less than 20% of a volume of each of the plurality of pulses of the gas comprising nitric oxide.

US Pat. No. 10,918,818

PATIENT INTERFACE AND ASPECTS THEREOF

1. A nasal seal configured to be removably coupled to a frame of a patient interface, the nasal seal comprising:a seal body formed of a soft flexible material and defining an inner cavity, the seal body comprising a first delivery opening and a second delivery opening for supply of breathing gases from the inner cavity to the patient, the seal body further comprising a nostril locator associated with and forming a portion of each of the first and second delivery openings;
wherein the seal body comprises a central portion and a pair of side portions extending from opposing ends of the central portion, the seal body further comprising an interior side and an exterior side, wherein a portion of the interior side within the central portion is configured to extend across a base of a user's nose and a portion of the interior side within each of the side portions is configured to extend across a side of the user's nose, wherein the interior side of the seal body is supple and configured to conform under internal pressure to surfaces of the user's nose, including, at the side portions of the seal body, to outside surfaces of the side of the user's nose, wherein each of the side portions defines a transition portion between the exterior side and the interior side, wherein the exterior side of each of the side portions comprises stiffened regions that are stiffer than the supple interior side, the stiffened regions extending toward the transition portions, wherein deflection regions are defined within an annular transition portion between each of the nostril locators and a corresponding surrounding portion of the interior side, wherein each of the deflection regions has a lower stiffness relative to other regions of the annular transition portion not within the deflection region to allow preferential deflection of each of the nostril locators in an outward direction, towards a laterally outer side of each of the nostril locators, wherein the annular transition portion is only formed from a homogenous material, wherein the lower stiffness is achieved by the deflection regions having a smaller thickness than the other regions of the annular transition portion, wherein each of the deflection regions is located only on the laterally outer side of a major axis of each of the nostril locators, wherein the major axis of each of nostril locators is defined along a largest width of each of the nostril locators.

US Pat. No. 10,918,817

VENTILATION

Oslo Universitetssykehus ...

1. A non-transitory computer readable medium comprising instructions that when executed on a controller will configure the controller to be arranged to perform a method, the method comprising:receiving a measurement of transthoracic impedance of a patient obtained during chest compressions, wherein the measurement of transthoracic impedance comprises measuring fluctuations in transthoracic impedance in the thoracic cavity generated by chest compressions to determine when the chest compressions are performed;
determining a first time period between the chest compressions based on the measurement of transthoracic impedance;
determining a timing for a mechanical ventilator to perform a ventilation between chest compressions for a second time period that is less than the first time period;
sending a signal to control the mechanical ventilator based on the determined timing; and
providing a mechanical ventilation based on the signal.

US Pat. No. 10,918,816

COMPLIANCE MONITORING MODULE FOR A BREATH-ACTUATED INHALER

Norton (Waterford) Limite...

1. An inhaler for delivering a dose of medicament to treat a respiratory condition, the inhaler comprising:a mouthpiece comprising a flow channel through which the dose of medicament can be delivered to a user;
a barometric pressure sensor pneumatically coupled to the flow channel, wherein the barometric pressure sensor is configured to measure a barometric pressure change within the inhaler resulting from an inhalation or an exhalation into the mouthpiece;
a processor electrically coupled to the barometric pressure sensor, wherein the processor is configured to determine a value indicative of the inhalation or the exhalation into the mouthpiece based on the pressure change;
a first housing that includes a reservoir comprising the medicament; and
a second housing mechanically coupled to the first housing, wherein the second housing includes the barometric pressure sensor and the processor.

US Pat. No. 10,918,815

INSUFFLATION RETENTION DEVICE WITH BALLOON

BPENDO, LLC, Norman, OK ...

1. An insufflation retention device comprising:an internal buttress configured to inhibit removal of the internal buttress from a body cavity through a body aperture of a body, wherein the internal buttress has an unexpanded state and an expanded state after introduction of an expansion material;
an internal buttress portion coupled to the internal buttress, wherein the internal buttress portion has rigidity greater than the internal buttress in the expanded state;
an external buttress coupled to the internal buttress, the external buttress configured to inhibit entry of the external buttress into the body cavity through the body aperture;
a passageway extending through the internal buttress and the external buttress that is configured for passage of a probe in contacting engagement with the body cavity, wherein the passageway is configured to be open without the probe present in the passageway such that an insufflation material introduced into the body cavity is not retained in the body cavity, and the internal buttress in the expanded state extends around and over an end of the internal buttress portion into the passageway for contacting engagement with the probe; and
a seam runs from an exterior surface of the passageway through to an interior surface of the passageway, wherein the seam extends from the internal buttress to the external buttress.

US Pat. No. 10,918,814

INSUFFLATING OPTICAL SURGICAL INSTRUMENT

Applied Medical Resources...

1. An insufflating surgical instrument adapted for movement across an abdominal wall to insufflate an abdominal region of a patient, comprising:a cannula comprising a lumen extending along an axis between a proximal end and a distal end; and
a trocar having a proximal end and a distal end, the trocar comprising:
a shaft arranged such that it may be inserted into the cannula, the shaft having an insufflation channel and a diameter sized to enable insertion of a laparoscope;
a tip at a distal end of the shaft and enclosing the distal end of the shaft to prevent instruments from extending through the distal end of the shaft, the tip having a pair of fins on an outer surface of the tip;
a plurality of shaft vents being in connection with the insufflation channel and formed along the shaft;
at least one vent hole formed at the tip between the pair of fins, the vent hole being in connection with the insufflation channel and being adapted to expel gas under pressure to insufflate the abdominal region;
wherein, in an assembled, operational configuration, the trocar is arranged to be insertable into and removable from the lumen of the cannula and the trocar is configured to permit a user to apply a force to the shaft to cause the tip to penetrate tissue ahead of the distal end of the cannula.

US Pat. No. 10,918,813

CARBOXY THERAPY APPLICATOR

NORTHGATE TECHNOLOGIES IN...

1. A method for monitoring and controlling a flow of gas within a handheld carboxy therapy applicator, the method comprising:reading a flow rate pressure and a volume of gas flow through the handheld carboxy therapy applicator with a pressure sensor and a flow detector positioned in the handheld carboxy therapy applicator; and
automatically controlling, with a microprocessor control unit positioned in the handheld carboxy therapy applicator, a flow rate, pressure, and volume of the gas flow through the handheld carboxy therapy applicator based on the reading of the flow rate pressure and the volume of gas through the handheld carboxy therapy applicator.

US Pat. No. 10,918,812

ESSENTIAL OILS DIFFUSER

SPDI HOLDINGS, INC., Alp...

1. A device for diffusing essential oils into the air, the device comprising:a reservoir;
a controller assembly, wherein the controller assembly includes:
a micro air pump having an air intake and a pressurized air outlet; and
an LED lighting the reservoir;
a tube in fluid connection between the pressurized air outlet of the micro air pump and extending into the reservoir, the tube providing a path for pressurized air from the micro air pump into the reservoir below an oil level in the reservoir body; and
an outlet for the air with infused essential oils to disperse into the air around the device and away from the air intake of the micro air pump.

US Pat. No. 10,918,811

AUDIBLE INDICATOR

Sanofi-Aventis Deutschlan...

1. An audible indicator for use with a drug delivery device, the audible indicator comprising: a monostatic resilient force member configured to reside in two or more states having two or more different conformations, wherein in a relaxed state, the monostable resilient force member is relaxed in a first conformation, wherein in a biased state, the monostable resilient force member is biased to store energy in a second conformation different from the first conformation and configured to remain in the second conformation while a first force is maintained, the first force being lower than a force needed for changing from the relaxed state to the biased state, and wherein the monostable resilient force member releases the stored energy to generate an audible signal when changing from the biased state into the relaxed state due to a transition from the second conformation to the first conformation, wherein the monostable resilient force member is supported by a retaining element in the biased state in order to prevent the transition into the relaxed state.

US Pat. No. 10,918,810

THERMAL TREATMENT OF SURGICAL FLUIDS

Microtek Medical, Inc., ...

25. A system for heating surgical fluid comprising:a base mounted on wheels;
a basin supported by and vertically elevated above the base, the basin being configured to receive and hold a surgical fluid;
a heater thermally coupled to the basin and configured to increase a temperature of the surgical fluid in the basin;
a weight measurement device positioned to obtain weight information concerning a weight of the basin and any contents therein;
a user interface configured to receive a user an at least one indication provided by a user that surgical fluid is to be added to the basin; and
a controller configured to receive weight measurement information from the weight measurement device concerning the weight of surgical fluid in the basin during the course of a procedure, receive at least one indication via the user interface that surgical fluid is to be added to the basin during the procedure, and determine the volume of surgical fluid removed from the basin based on the received weight measurement information and the received at least one indication, wherein the controller is configured to determine the volume of surgical fluid removed from the basin during the procedure by at least distinguishing a weight change in the basin corresponding to the at least one indication indicating addition of surgical fluid from the weight change in the basin attributable to addition or removal of a non-fluid component.

US Pat. No. 10,918,809

SINGLE USE DELIVERY DEVICE HAVING A PRIMER ELEMENT

Becton, Dickinson and Com...

1. A single use delivery device comprising:a manually deformable liquid container defining two or more inner chambers, the container having a distal end, a proximal end, and an outlet on the distal end;
a tip projecting from the outlet on the distal end of the container, the tip in fluid communication with the inner chamber of the container;
a primer element for collapsing a portion of the deformable container for driving air out of said chamber by depressing the primer element, said primer element being attached to the deformable container; and
two or more one-way valves, wherein at least one of the two or more one-way valves is disposed between the two or more inner chambers, and at least one of the two or more one-way valves is disposed between the primer and the outlet, the two or more one-way valves in fluid communication with the two or more inner chambers of the container, said two or more one-way valves permitting air or fluid evacuation from the inner chamber but preventing air or fluid intake into the inner chamber when the container is manually deformed and released.

US Pat. No. 10,918,808

ANGLED INJECTION NOZZLE

Portal Instruments, Inc.,...

1. An adapter for use with an injection device, the adapter comprising a body including:a first end, a second end and a first longitudinal axis extending from the first end and the second end,
a chamber defined by a sidewall between the first end and second end,
a nozzle having an input, an output opening, and a passageway from the input to the output opening, the passageway having an injection axis extending through the input and the output opening and to an outer surface of the body, the output opening and the injection axis being angularly offset from the first longitudinal axis of the body;
wherein the output opening of the nozzle is spaced from an injection site during injectate delivery to the injection site, and wherein a plunger is configured to fit into a depression of the adapter in which the injectate pools prior to ejection.

US Pat. No. 10,918,807

DISPOSABLE PEN NEEDLE WITH ABBREVIATED NON-PATIENT END, AND REUSABLE PEN INTERFACE

Becton, Dickinson and Com...

1. A disposable pen needle, comprising:a hub having a distal hub portion, a proximal hub portion adapted for attachment to a medicament delivery device, and a hub bore extending through the hub from the distal hub portion to the proximal hub portion, and
a needle mounted to the hub, the needle having a distal injection end and a proximal needle portion that is not exposed, the proximal needle portion terminating in a non-injection end,
wherein at least part of the proximal needle portion resides in the hub bore, and
wherein the distal hub portion and the proximal hub portion are separately formed parts, each having a respective hub bore segment, the hub portions being joined together with their hub bore segments aligned; and
wherein the non-injection end of the needle is split into a plurality of legs that are turned outward and sandwiched between the distal hub portion and the proximal hub portion.

US Pat. No. 10,918,806

SAFE SYRINGE

1. A safe syringe, comprising:a barrel having a barrel body, an accommodating chamber, a seat mounting hole and a seat clamping slot;
a needle seat having a seat body mounted in the seat mounting hole of the barrel, a needle hole, a hook rod, a linkage deformation portion connected to the hook rod, and a barrel clamping portion connected to the linkage deformation portion, linked thereby and capable of being clamped into the seat clamping slot of the barrel; and
a plunger having a rod body, and a hook insertion hole which is capable of being sleeved with the hook rod of the needle seat and compressing the linkage deformation portion for elastic deformation such that the barrel clamping portion of the needle seat is not clamped into the seat clamping slot of the barrel, the hook insertion hole being capable of hooking the hook rod of the needle seat to move the needle seat,
wherein the hook rod is mounted at a tail of the linkage deformation portion so that the linkage deformation portion and the hook rod form an asymmetrical one-sided arc structure.

US Pat. No. 10,918,805

AUTOINJECTOR APPARATUS

AMGEN INC., Thousand Oak...

1. A single-use cassette for use with an autoinjector, the cassette comprising:a housing;
an inner sleeve disposed in the housing and movable between first and second positions along a longitudinal axis, the inner sleeve comprising one or more side walls defining an interior, and at least one receptacle having a rearward opening, the at least one receptacle separate from and disposed adjacent to the interior;
a syringe disposed in the interior of the inner sleeve; and
lock cap for securing the syringe in the inner sleeve, the lock cap including an elastomeric bumper, the lock cap affixed to a distal end of the inner sleeve with the elastomeric bumper contacting a distal end of the syringe, wherein the lock cap comprises at least one arm member extending generally parallel to the longitudinal axis for inserting into the at least one receptacle.

US Pat. No. 10,918,804

MEDICAMENT INJECTION DEVICE WITH SPRING-ASSISTED PROTECTIVE NEEDLE CAP

Sanofi-Aventis Deutschlan...

1. A medicament injection device comprising:a main body;
a medicament cartridge holder fixed with respect to the main body, herein the medicament cartridge holder is configured to hold a medicament cartridge;
a needle carrier carrying a needle, wherein the needle carrier is axially movable with respect to the main body;
a rotatable cap at a distal end of the medicament injection device, wherein the cap comprises a first pre-stressed spring coupled to the needle carrier; and
at least one activation element configured to control the release of the first pre-stressed spring,
wherein the first pre-stressed spring is attached at a proximal end thereof to a plate, and wherein rotation of the cap from a first position in which the at least one activation element is in blocking engagement with the plate to a second position in which the at least one activation element is out of blocking engagement with the plate causes the plate and the first pre-stressed spring to be released, thereby causing the plate to push the needle carrier towards a proximal end of the medicament injection device.

US Pat. No. 10,918,803

SYRINGE CARRIER FOR AN AUTOINJECTOR AND METHOD OF ASSEMBLING

Sanofi-Aventis Deutschlan...

1. A syringe carrier comprising:a housing adapted to receive a syringe having a needle encapsulated by a removable protective needle sheath; and
two or more flexible arms protruding inwards in a relaxed state, or extending straightly in a relaxed state, and adapted to couple with the syringe in a mounted position,
wherein the two or more flexible arms are adapted to deflect radially outwards in a pre-assembled position of the syringe in the syringe carrier,
wherein the two or more flexible arms comprise protrusions at a distal end of the two or more flexible arms which are inwardly directed at an angle related to the distal end of the two or more flexible arms, and
wherein a respective distal end of the two or more flexible arms forms a respective distal end of the syringe carrier.

US Pat. No. 10,918,802

NEEDLE EXCHANGE SYSTEM

A to Z Technologies, LLC,...

1. A system for facilitating exchange of needles on syringes, the system comprising:a needle exchange device elongated along a longitudinal axis with opposite first and second ends, the needle exchange device forming a needle receiving sheath for receiving at least a portion of a needle device mounted on a syringe to be discarded, the needle receiving sheath defining an insertion opening and an elongated channel in communication with the insertion opening to receive the at least a portion of a needle device, the needle exchange device forming a needle assembly dispensing pocket defining an elongated dispensing cavity and having a cavity opening; and
a needle assembly at least partially received in the dispensing cavity of the needle assembly dispensing pocket of the needle exchange device, the needle assembly being removable as a unit from the needle assembly dispensing pocket, the needle assembly including:
a needle device with a needle; and
a protective sleeve positioned over at least the needle of the needle device;
wherein the needle receiving sheath of the needle exchange device is empty of any needle device such that the needle receiving sheath is ready to accept a needle device from a syringe;
wherein an axis along which the channel of the needle receiving sheath is elongated and an axis along which the cavity of the needle assembly dispensing pocket is elongated are oriented substantially parallel to the longitudinal axis of the needle exchange device;
wherein the needle receiving sheath and the needle assembly dispensing pocket are substantially oppositely oriented on the exchange device such that the insertion opening of the needle receiving sheath is located at the first end of the needle exchange device and the cavity opening of the needle assembly dispensing pocket is located at the second end of the needle exchange device opposite of the insertion opening;
wherein an interior of the dispensing cavity of the needle assembly dispensing pocket is differently configured from an interior of the elongated channel of the needle receiving sheath to facilitate at least partial insertion of the protective sleeve of the needle assembly and to facilitate insertion of the needle device without the protective sleeve in the elongated channel of the needle receiving sheath for disposal; and
wherein a cross-section of an interior of the needle assembly dispensing pocket has a rectangular shape configured to engage an exterior of the protective sleeve of the protective device of the needle assembly; and
wherein a cross-section of an interior of the needle receiving sheath has a substantially circular shape to engage an exterior of a needle device on a syringe.

US Pat. No. 10,918,801

CAPS FOR INTEGRATED FILL AND INJECT OF SAFETY NEEDLE DEVICES

Becton, Dickinson and Com...

1. A drug delivery safety device comprising:a safety needle device comprising a needle hub, a needle cannula, and a safety feature; and
a cap comprising a cap body having a proximal end attached to the safety needle device and a distal end having an access opening that is in fluid communication with the needle cannula, the access opening comprises an access protrusion extending from the distal end of the cap, the cap further comprises a blunt fill cannula extending from a distal end of the access protrusion and in fluid communication with the needle cannula and a seal between the blunt fill cannula and an inside surface of the access protrusion.

US Pat. No. 10,918,800

CONVERTIBLE PLUNGERS AND METHODS FOR ASSEMBLING THE SAME IN A MEDICAL BARREL

SIO2 MEDICAL PRODUCTS, IN...

1. A convertible plunger for disposition within a barrel of a medical container, the barrel being configured for receipt of an injectable product therein and having a central axis and an interior wall surrounding the axis, the plunger being configured to be moved within the barrel along the axis from a storage mode to a dispensing mode, the plunger comprising:a. a ring carrier having a compressible and resilient storage ring disposed thereon, the storage ring being configured for axial displacement along the ring carrier, the ring carrier comprising:
i. an annular storage platform that is comparatively more rigid than the storage ring, the storage ring being in an expanded state corresponding to an engagement position when the storage ring is disposed about the storage platform, wherein a storage sealing section of the storage ring is configured to apply outward radial pressure on the interior wall of the barrel;
ii. an annular dispensing platform having a narrower cross-sectional width or diameter than that of the storage platform, the storage ring being in a constricted state corresponding to a release position when the storage ring is disposed about the dispensing platform, wherein the storage sealing section is configured to provide less radial pressure on the interior wall than when in the engagement position or to provide no outward radial pressure on the interior wall; and
iii. an annular insertion platform, the insertion platform having a smaller maximum diameter or cross-sectional width than that of the storage platform, the storage ring being in a load position when the storage ring is disposed about the insertion platform so as to facilitate insertion of the ring carrier and storage ring into the barrel, wherein the storage sealing section is configured to provide less radial pressure on the interior wall than when in the engagement position or to provide no outward radial pressure on the interior wall, the storage ring being configured to move along the ring carrier between the load position, the engagement position and the release position; and
b. a plunger head mounted at a distal end of the plunger, the plunger head having a liquid sealing section configured to contact and provide a seal against the interior wall, wherein the plunger head is a separate component assembled with the ring carrier to form the convertible plunger.

US Pat. No. 10,918,799

DRIVE MECHANISM AND DRUG DELIVERY DEVICE HEREWITH

Sanofi, Paris (FR)

10. A drug delivery device comprising:a cartridge containing a medicament,
a drive mechanism comprising:
a base element,
a toothed piston rod, comprising multiple rigid rod pieces comprising a first rigid rod piece comprising a circular pressure foot and a plurality of further rigid rod pieces, the toothed piston rod being guided within and movable relative to the base element, and
a drive gear having a pinion, which is rotatably held in the base element and in meshed engagement with the toothed piston rod,
wherein each of the plurality of further rigid rod pieces consists of:
a corresponding flat plate provided with a corresponding straight toothed rack, and
a corresponding flange located on an opposite side of the corresponding straight toothed rack,
wherein the corresponding flat plate together with the corresponding straight toothed rack is located offset from a center of the circular pressure foot,
wherein outer dimensions of the multiple rigid rod pieces are adapted to inner dimensions of the cartridge such that each of the plurality of further rigid rod pieces is guided within the cartridge by two axially extending edges of the corresponding flange and by two axially extending edges of the corresponding flat plate, and
wherein end faces of the multiple rigid rod pieces are planar, and when the toothed piston rod is straightened, adjacent faces of the multiple rigid rod pieces abut each other,
a dose setting member for setting user variable doses of the medicament,
a display for indicating a dose set by the dose setting member, and
a coupling member interposed between the drive gear and the dose setting member.

US Pat. No. 10,918,798

MEDICAMENT INJECTION DEVICE

Sanofi-Aventis Deutschlan...

1. A medicament injection device comprising:a main body configured to receive a medicament cartridge sealed by a penetrable barrier;
a cap assembly having an inner needle part and an outer needle part, wherein the inner needle part is movable in a proximal direction with respect to the outer needle part;
a needle carrier carrying a needle, the needle carrier being releasably coupled to the inner needle part;
a medicament cartridge holder configured to hold the medicament cartridge, the medicament cartridge holder comprising a needle carrier support part having a distal flange configured to support the needle carrier away from the medicament cartridge before displacement of the needle carrier and adapted to fix the needle carrier to the medicament cartridge subsequent to axial displacement of the needle carrier; and
a needle sleeve coupled to the cap assembly by a frictional fit,
wherein, when the inner needle part is displaced in the proximal direction, the inner needle part causes the needle carrier to be displaced axially in the proximal direction, and
wherein, subsequent to axial displacement of the inner needle part, the cap assembly is separable from the main body by movement of the cap assembly in a distal direction, and
wherein the outer needle part comprises a ridge arranged to abut a flange of the needle sleeve so that movement of the cap assembly in the distal direction is prevented prior to displacement of the inner needle part in the proximal direction.

US Pat. No. 10,918,797

SYRINGE FOR DIRECT USE WITH MEDICAL AMPOULES AND VIALS

S-VIAL Ltd., Or Akiva (I...

1. A kit for the direct use of a variety of medical ampoules of differing sizes, with a syringe, the kit comprising:(a) a syringe body;
(b) a syringe plunger configured for insertion into said syringe body, said syringe plunger having a hollow interior volume which is open at one end; and
(c) a plurality of ampoule interface elements, each one of said plurality of ampoule interface elements being a sheath including:
(i) a bottom portion,
(ii) a top portion, and
(iii) break lines intervening between said top portion and said bottom portion, such that said sheath is breakable along said break lines;
wherein said sheath is adapted to be deployed, in a first state, over a respective corresponding ampoule of the variety of medical ampoules, such that said bottom portion is deployed on a medicine containing bottom portion of said respective corresponding ampoule and said top portion is deployed on a top breakaway portion of said respective corresponding ampoule,
and in a second state, only said bottom portion being deployed over said medicine containing bottom portion of said respective corresponding ampoule, said top breakaway portion having been detached and discarded with said top portion;
wherein each of said ampoule interface elements, in said second state, is adapted to be interchangeably received within said hollow interior volume and configured for deployment between an outer surface of a respective, corresponding ampoule of the variety of medical ampoules and a surface defining said hollow interior volume so as to hold said respective, corresponding ampoule in said hollow interior volume, each of said plurality of ampoule interface elements having an outside diameter sized to fit closely against an inside diameter of said hollow interior volume of said syringe plunger,
wherein said plurality of ampoule interface elements includes at least: a first of said ampoule interface elements that has a first inside diameter for receiving a medical ampoule of a first size, and
a second of said ampoule interface elements that has that has a second inside diameter different from said first inside diameter for receiving a medical ampoule of a second size.

US Pat. No. 10,918,796

SYRINGE FOR MIXING TWO COMPONENTS AND FOR RETAINING A VACUUM IN A STORAGE CONDITION

1. A syringe for retaining and mixing first and second substances comprising:a barrel comprising a sealable and/or closable distal outlet and a vacuum chamber for retaining the first substance in a vacuum,
a plunger incorporating a reservoir chamber for holding the second substance and configured to be axially displaced through a proximal end of the barrel,
a membrane separating the vacuum chamber and the reservoir chamber, and
a pointed member for penetrating the membrane,wherein the syringe is configured such that the vacuum in the vacuum chamber pulls the plunger without involvement of a manual force on the plunger to effectuate an axial displacement of the plunger from a first position in which the pointed member does not penetrate the membrane to a predefined second position in the barrel and this axial displacement of the plunger penetrates the membrane by the pointed member and establishes a fluid passageway between the reservoir chamber and the vacuum chamber whereupon the vacuum in the vacuum chamber aspirates the second substance into the vacuum chamber thereby transferring the second substance of the reservoir chamber into the vacuum chamber without displacement of the plunger from said predefined second position.

US Pat. No. 10,918,795

MEDICAL DELIVERY DEVICE

HOFFMANN-LA ROCHE INC, L...

1. A medical delivery device, comprising:a rod element having a stem with a longitudinal axis, a distal end and a proximal end;
a dosage member comprising a delivery orifice and a chamber body with a distal end, a proximal end and a hollow interior, wherein the stem of the rod element extends into the interior of the chamber body of the dosage member and the delivery orifice is arranged adjacent to the proximal end of the stem of the rod element; and
a lock mechanism for changing the medical delivery device from a lock status to a dosing status, wherein
in the dosing status of the medical delivery device, the lock mechanism is disengaged whereby the rod element is movable along its longitudinal axis relative to the delivery orifice of the dosage member, such that a dosage chamber is formed in the interior of the chamber body of the dosage member between the stem of the rod element and the delivery orifice which dosage chamber increases when the rod element moves away from the delivery orifice, and
in the lock status of the medical delivery device, the lock mechanism is engaged to thereby prevent movement of the rod element along its longitudinal axis relative to the delivery orifice of the dosage member.

US Pat. No. 10,918,794

MEDICAL DELIVERY DEVICE

HOFFMANN-LA ROCHE INC., ...

1. A medical delivery device, comprising:a rod element having a stem with a longitudinal axis, a first thread arrangement, a distal end and a proximal end; and
a dosage member comprising a delivery orifice and a chamber body with a distal end, a proximal end and a hollow interior, wherein the stem of the rod element extends into the interior of the chamber body of the dosage member and the delivery orifice is arranged adjacent to the proximal end of the stem of the rod element,
wherein, in a dosing status of the medical delivery device,
the rod element is movable along its longitudinal axis relative to the delivery orifice of the dosage member by the first thread arrangement of the rod element and a second thread arrangement travelling along each other, wherein a dosage chamber is formed in the interior of the chamber body of the dosage member between the stem of the rod element and the delivery orifice which dosage chamber increases when the rod element moves away from the delivery orifice, and
the dosage member comprises the second thread arrangement, wherein, in the dosing status of the medical delivery device, the first thread arrangement of the rod element engages the second thread arrangement of the dosage member.

US Pat. No. 10,918,793

MEDICAL DELIVERY DEVICE

HOFFMANN-LA ROCHE INC., ...

1. A medical delivery device comprising:a rod element having a stem with a longitudinal axis, a first thread arrangement, a distal end and a proximal end;
a dosage member comprising a delivery orifice, a second thread arrangement, and a chamber body with a distal end, a proximal end and a hollow interior, wherein the stem of the rod element extends into the hollow interior of the chamber body of the dosage member and the delivery orifice is arranged adjacent to the proximal end of the stem of the rod element; and
a switching mechanism for changing the medical delivery device from a dosing status to a delivery status, the switching mechanism including a disengaging structure,
wherein in the dosing status of the medical delivery device,
the rod element is movable along its longitudinal axis relative to the delivery orifice of the dosage member by the first thread arrangement of the stem of the rod element and the second thread arrangement of the dosage member engaging with and travelling along each other, wherein a dosage chamber is formed in the interior of the chamber body of the dosage member between the stem of the rod element and the delivery orifice which dosage chamber increases when the rod element moves away from the delivery orifice, and moving the rod element along its longitudinal axis by applying an axial force to the rod element is prevented by the engagement between the first thread arrangement of the stem of the rod element and the second thread arrangement of the dosage member, and
wherein in the delivery status of the medical delivery device,
the rod element is movable along its longitudinal axis relative to the delivery orifice by applying an axial force to the rod element, and moving the rod element along its longitudinal axis by travelling the first thread arrangement of the stem of the rod element and the second thread arrangement along each other is prevented by the disengaging structure of the switch element which disengages the first thread arrangement of the stem of the rod element from the second thread arrangement of the dosage member upon changing the medical delivery device from the dosing status to the delivery status.

US Pat. No. 10,918,792

HOUSING PART FOR AN AUTO-INJECTOR

USB Biopharma SPRL, Brus...

1. A housing part for an auto-injector comprising:a shell form body defining inner and outer shell surfaces;
an over-coating, said over-coating covering at least part of said outer shell surface of said shell form body; and
at least one window defined in the shell form body, wherein said over-coating extends into said at least one window,
wherein a material forming the over-coating is softer than or is more compressible than a material forming the shell form body, and
wherein the over-coating extends into the window beyond a depth of the inner shell surface to define an inwardly protruding element,
wherein the inwardly protruding element is configured to be disposed between the shell form body and at least one functional element to be disposed within the housing part so as to provide impact protection for the at least one functional element within the housing part,
wherein the inner shell surface adjacent the at least one window is free of said over-coating.

US Pat. No. 10,918,791

DEVICES, SYSTEMS AND METHODS FOR MEDICAMENT DELIVERY

kaleo, Inc., Richmond, V...

11. A method of delivering a medicament, comprising:placing a distal end surface of a base of a medical injector into contact with a body, the medical injector including a housing, a medicament container within the housing, a movable member, a needle, an energy storage member, a valve, and an expandable assembly coupled between the movable member and the valve; and
actuating the medical injector to cause the energy storage member to produce a pressurized gas within a gas chamber defined by the housing, the pressurized gas exerting a force to: A) move the needle from a first needle position, in which the needle is within the housing, to a second needle position, in which a portion of the needle is outside of the housing and B) move the movable member within the medicament container to convey the medicament from the medicament container via the needle,
the expandable assembly transitioning from a first configuration to a second configuration when the movable member moves within the medicament container, the expandable assembly actuating the valve to release the pressurized gas from the gas chamber when the expandable assembly is transitioned from the first configuration to the second configuration.

US Pat. No. 10,918,790

DUAL SYRINGE WITH FUNNEL FEEDING KIT

Guangzhou Bioseal Biotech...

1. A multi-liquid loading and delivery kit comprising:a) a first storage vessel for a first active component; b) a second storage vessel for a second active component; c) at least two transfer syringes; d) at least two vial adaptors; e) at least two cannulas with a through lumen; and f) a multi-liquid delivery device comprising:
a. dual hollow cartridges, each with at least one throughbore at one end and plunger access at an opposing end;
b. a rotatable kick stand;
c. a removable dual feed funnel;
d. a spray manifold; and
e. at least one spray tip assembly or drip tip assembly, wherein the removable dual feed funnel is interchangeable with the spray manifold.

US Pat. No. 10,918,789

METHODS AND SYSTEMS FOR CONTROLLING AN INFUSION PUMP

DEKA Products Limited Par...

1. An infusion pump system comprising:an infusion pump, wherein the infusion pump comprising at least one temperature sensor;
a controller device comprising a touch screen display and generating system alarms, recoverable alarms and alerts; and
a first user interface residing on the controller, the first user interface comprising an insulin temp alert notification,
wherein a system alarm disallows pump operation and cannot be overrode by a user, a recoverable alarm disallows pump operation until the user takes certain action, an alert allows the pump operation while notifying the user of a condition, and the insulin temp alert notification appears on the first user interface when the internal temperature of the infusion pump exceeds a threshold preset temperature or is less than a threshold preset temperature.

US Pat. No. 10,918,788

DRIVE MECHANISM FOR DRUG DELIVERY PUMPS WITH INTEGRATED STATUS INDICATION

UNL HOLDINGS LLC, New Yo...

1. A drive mechanism having integrated incremental status indication comprising:a drive housing;
a drive biasing member;
a piston;
an incremental status stem having a stem interconnect mounted, affixed, printed, or otherwise attached thereon; and
a drug container having a cap, a pierceable seal, a barrel, and a plunger seal, wherein the incremental status stem resides within axial pass-throughs of the drive housing and the piston, and wherein the drive biasing member is configured to bear upon an interface surface of the piston.

US Pat. No. 10,918,787

DISPOSABLE INFUSION FLUID DELIVERY DEVICE FOR PROGRAMMABLE LARGE VOLUME DRUG DELIVERY

ICU Medical, Inc., San C...

10. An infusion pump system comprising:a non-disposable microcontroller comprising:
a first microprocessor;
a first memory in electronic communication with the first microprocessor;
a power source;
a power transmitter connected to the power source and configured to wirelessly transmit power; and
a first wireless communication device;
a single disposable infusion container configured to contain infusion fluid;
a plurality of disposable electronically controlled medication pumping systems, each of the plurality of disposable electronically controlled medication pumping systems powered and controlled by the non-disposable microcontroller, each of the plurality of disposable electronically controlled medication pumping systems fluidly connected to the single disposable infusion container and in parallel with each other, each of the plurality of disposable electronically controlled medication pumping systems comprising:
a second microprocessor;
a second memory in electronic communication with the second microprocessor;
a power receiver configured to wirelessly receive the power from the power transmitter;
a second wireless communication device configured to wirelessly communicate with the first wireless communication device;
an infusion channel;
a disposable electronically controlled micropump configured to pump the infusion fluid through the infusion channel; and
valves connected to the infusion channel,
wherein the infusion channels of the plurality of disposable electronically controlled medication pumping systems are joined together with a connector downstream of the disposable electronically controlled micropumps of the plurality of disposable electronically controlled medication pumping systems.

US Pat. No. 10,918,786

METHOD FOR MANUFACTURING A CANNULA UNIT

Roche Diabetes Care, Inc....

1. A method for manufacturing a cannula assembly, comprising:injection molding a cannula onto a molding core pin having an outer diameter d1 to produce a cannula having a distal end with a larger outer diameter than the outer diameter of the remaining cannula, a first distal section adjoining the distal end, a second proximal section adjoining the first distal section, and a proximal end;
injection molding a cannula housing onto the distal end and the first distal section of the cannula;
removing the molding core pin from the cannula; and
threading a piercing needle with an outer diameter d4 into the cannula, wherein the diameter d4 of the piercing needle is chosen such that it is smaller than the diameter d1 of the molding core pin.

US Pat. No. 10,918,785

INTEGRATION OF INFUSION PUMP WITH REMOTE ELECTRONIC DEVICE

Tandem Diabetes Care, Inc...

1. A method of providing medicament therapy to a patient with a medical infusion pump, comprising:determining an operation to be performed by the medical infusion pump;
transmitting information pertaining to the determined operation to a caregiver device;
displaying an authorization request on the caregiver device to execute the determined operation with the medical infusion pump;
receiving authorization at the caregiver device in response to the authorization request;
transmitting an authorization command to execute the determined operation from the caregiver device to the medical infusion pump; and
causing the medical infusion pump to execute the determined operation after receiving the authorization command.

US Pat. No. 10,918,784

HOLDING MEMBER AND PACKAGING STRUCTURE OF CHEMICAL CONTAINER PARTS

DAIKYO SEIKO, LTD., Toch...

1. A holding member that is configured to hold a plurality of syringe pistons, the holding member comprising:a sheet-shaped substrate portion having a first surface and a second surface;
a plurality of storage portions each penetrating the first surface and the second surface of the substrate portion and each protruding in a direction of a side of the first surface and in a form of a cylinder, and each storage portion being configured to store an entire portion of one of the plurality of the syringe pistons therein; and
a plurality of connection ribs located outside the cylinder of each of the plurality of the storage portions, the plurality of the connection ribs each connecting the storage portions adjacent to each other among the plurality of the storage portions,
wherein the plurality of the storage portions each comprises:
a first opening end portion forming a loading and unloading mouth for the one of the plurality of the syringe pistons at a protruded tip of each of the plurality of the storage portions;
a bulging portion where an inner wall face of each of the plurality of the storage portions on a side of the first opening end portion bulges continuously from the first opening end portion in a direction of an inside of the cylinder, thereby forming an opening widened toward the first opening end portion;
a second opening end portion formed at a base end of each of the plurality of the storage portions by the second surface of the substrate portion; and
a tapered-off portion where the inner wall face of each of the plurality of the storage portions on a side of the second opening end portion is formed in such a way as to narrow an opening toward the second opening end portion, and
wherein each of the plurality of the connection ribs is formed at a position lower than a height of the bulging portion of each of the plurality of the storage portions from the first surface of the substrate portion.

US Pat. No. 10,918,783

PROBE TIP AND INFUSION SLEEVE FOR USE IN OPHTHALMOLOGICAL SURGERY

1. A phacoemulsification probe for use with eye surgery, comprising:a connector for interconnecting the phacoemulsification probe with a phacoemulsification machine; and
a probe tip having a first end with a first central axis running therethrough connected with the connector and a second end with a second axis running therethrough, wherein the second axis is at a predetermined angle to the first central axis, wherein the probe tip further includes a body defining a first channel therein for aspirating material therethrough from a surgical region within an eye through an opening in the second end along a first vector along the second axis into the first channel, the body including a straight portion around the first central axis connected to the first end and a curved portion connecting the straight portion to the second end;
a metal ledge extending outward from an edge of the second end of the probe tip for a predetermined distance, wherein the metal ledge only extends outward from the edge of the second end of the probe tip along a portion of a circumference of the second end; and
a fluid sleeve surrounding at least a portion of the probe tip and having a first end and a second end, the fluid sleeve having a first portion at the first end of the fluid sleeve having a first size that prevents the fluid from flowing between the fluid sleeve and the body of the probe tip, the fluid sleeve further having a second portion having a second size that defines a second channel between an inner surface of the fluid sleeve and an outer surface of the body of the probe tip for injecting the fluid into the surgical region within the eye, the fluid sleeve defining at least one opening for injecting the fluid from the second channel into the surgical region of the eye along at least one second vector, the at least one second vector injecting the fluid into the surgical region of the eye in a non-competitive direction to the first vector of aspiration into the opening in the second end of the probe tip.

US Pat. No. 10,918,782

SYSTEMS AND METHODS FOR PLASMA SEPARATION AND UV IRRADIATION

1. A system for irradiating plasma, comprising:a blood outlet tube comprising an outlet arm end and a separator end, wherein blood from a patient flows through said blood outlet tube from said outlet arm end toward said separator end;
a plasma separator connected to said separator end of said blood outlet tube, wherein said plasma separator separates the blood into plasma and a cellular element;
a blood pump disposed between said outlet arm end and said separator end of said blood outlet tube such that said blood pump pumps the blood through said blood outlet tube and into said plasma separator;
means for exposing the plasma to ultraviolet (UV) radiation, wherein said exposing means comprise at least a plasma vessel with a plasma inlet and a plasma outlet, and at least one UV light source disposed such that said at least one UV light source exposes said plasma vessel to UV light;
a plasma inlet tube extending between said plasma separator and said plasma inlet of said exposing means, wherein the plasma travels through said plasma inlet tube;
a blood inlet tube comprising a joint end and an inlet arm end, wherein the cellular element and the irradiated plasma reunite at said joint end of said blood inlet tube and travel through said blood inlet tube as treated blood;
a plasma outlet tube extending between said plasma outlet of said exposing means and said joint end of said blood inlet tube;
a cellular element tube extending between said plasma separator and said joint end of said blood inlet tube, wherein the cellular element travels through said cellular element tube;
a plasma component separator disposed between said plasma separator and said exposing means, wherein said plasma component separator:
separates the plasma into small plasma and large plasma; and
divides said plasma inlet tube into:
a first section extending between said plasma separator and said plasma component separator; and
a second section extending between said plasma component separator and said exposing means;
a plasma pump disposed between said plasma separator and said plasma component separator such that said plasma pump pumps plasma through said first section of said plasma inlet tube into said plasma component separator; and
a small plasma tube extending from said plasma component separator to said cellular element tube, wherein the small plasma travels through said small plasma tube to reunite with the cellular element;
wherein:
the large plasma travels through said second section of said plasma inlet tube to said exposing means; and
the irradiated large plasma travels through said plasma outlet tube to reunite with the small plasma and cellular element at said joint end of said blood inlet tube.

US Pat. No. 10,918,781

APPARATUS, SYSTEM AND METHOD FOR A PRESSURE-BASED DETECTION OF A CLOT

FRESENIUS MEDICAL CARE DE...

1. An apparatus for a pressure-based detection of a clot in an extracorporeal blood circuit, wherein the apparatus comprises at least one cyclically operating pump for conveying the fluid located in the extracorporeal circuit and at least one pressure sensor which is arranged to determine the current pressure development over time in the fluid conveyed by the pump in a current conveying cycle of the pump, wherein the apparatus has at least one memory in which at least one reference pressure development is stored which is based on at least one pressure development over time which was determined in a conveying cycle of the pump preceding the current conveying cycle of the pump, wherein the apparatus comprises at least one sensor for detecting the position of the conveying member or members of the pump, with the sensor being connected to the evaluation unit for a comparison corresponding in time between the current pressure development and the reference pressure development, and wherein the apparatus comprises at least one evaluation unit which is configured such that it compares the current pressure development with the reference pressure development over a corresponding time.

US Pat. No. 10,918,780

SYSTEM AND METHOD OF CONTROLLING MEMBRANE FLUID FLOW USING FLUID OUTPUT

Fenwal, Inc., Lake Zuric...

1. A computer-implemented method for controlling fluid flow rates during a biological fluid procedure, comprising:providing a membrane separator configured to separate a biological fluid into filtrate and retentate, wherein concentration of retentate exiting the membrane separator is controllable by altering a flow rate of the retentate exiting the membrane separator;
detecting a change of attenuated retentate particles within the filtrate;
comparing the change of attenuated retentate particles within the filtrate with a threshold level; and
providing a first response action comprising altering the concentration of retentate exiting the membrane separator if the change of attenuated retentate particles within the filtrate exceeds the threshold level;
detecting a change in transmembrane pressure within the membrane separator;
comparing the change in transmembrane pressure with a second threshold level; and providing a second response action comprising increasing the flow rate of the retentate if the change in transmembrane pressure exceeds the second threshold level,
wherein the second response action is provided only when the first response action is not triggered; or
withholding the first response action when the second response action is ongoing.

US Pat. No. 10,918,779

CLEANING OF BIOLOGICAL FLUID

Gambro Lundia AB, Lund (...

1. A system configured to remove deleterious substances from blood or separated blood plasma, the system comprising:a blood circuit;
a fluid circuit;
a cleaning fluid;
and
a blood treatment unit comprising one or more semipermeable membranes separating a fluid compartment from a blood compartment configured to mix blood, or separated blood plasma, and the cleaning fluid;
wherein the cleaning fluid comprises a displacer substance, and the displacer substance is a combination of sodium octanoate with one or both of sodium salicylate and sodium acetylsalicylate.

US Pat. No. 10,918,778

DIRECT SODIUM REMOVAL METHOD, SOLUTION AND APPARATUS TO REDUCE FLUID OVERLOAD IN HEART FAILURE PATIENTS

Sequana Medical NV, Zwij...

1. An infusate for use in the treatment of heart failure by removing excess sodium, wherein the infusate is formulated to be administered by infusion into, and drainage from, a peritoneal cavity of a patient having at least residual kidney function with an estimated glomerular filtration rate greater than 15 ml/min/1.73 m2, the infusate comprising:an aqueous solution containing at least one of 0.5 to 50 grams of dextrose per 100 ml of aqueous solution, 0.5 to 50 grams of icodextrin per 100 ml of aqueous solution, 0.5 to 50 grams of a high molecular weight glucose polymer having an average molecular weight greater than 10,000 Daltons per 100 ml of aqueous solution, or any combination thereof; and
a sodium concentration equal to or less than 35 meq/L,
wherein the infusate removes excess sodium to cause a reduction in fluid overload in the patient while maintaining a serum sodium level substantially unchanged.

US Pat. No. 10,918,777

DELIVERY SYSTEM AND MODE OF OPERATION THEREOF

Debiotech S.A., Lausanne...

1. A dialysis system for performing a peritoneal dialysis by a defined treatment of a patient, the dialysis system comprising:a processor configured to control the dialysis system to deliver a dialysate solution with a plurality of delivery cycles to a peritoneum of the patient during the defined treatment;
a pressure sensor for measuring a pressure of the dialysate solution in a fluidic pathway and providing a pressure signal to the processor; and
a pump controlled by the processor and configured to displace the dialysate solution through the fluidic pathway to the patient,
wherein the processor is configured to,
control the pump to deliver the dialysate solution at a fluid delivery rate to the patient;
estimate a displaced volume of the dialysate solution delivered to the peritoneum based on measurements of the pressure sensor;
analyze the pressure signal from the pressure sensor of the dialysis system to determine a variation of the pressure of the dialysate solution from a threshold value caused by a failure condition of the dialysis system;
control the pump to reduce the fluid delivery rate of the dialysate solution to a reduced safe fluid delivery rate such that a cumulated error during the plurality of delivery cycles caused by of the variation of the pressure does not cause an overfilling the peritoneum by the delivered dialysate solution; and
determine a new threshold value for the analyzing the pressure signal based on the reduced safe fluid delivery rate.

US Pat. No. 10,918,776

APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD INCLUDING CALCULATION OF FLOW RATES THEREFORE

Gambro Lundia AB, Lund (...

1. An apparatus for extracorporeal treatment of blood comprising:a filtration unit including a primary chamber and a secondary chamber separated by a semi-permeable membrane;
a blood withdrawal line in fluid communication with an inlet of the primary chamber;
a blood return line in fluid communication with an outlet of the primary chamber, said blood withdrawal and return lines configured to connect to a patient;
a blood pump configured to pump blood through at least one of the blood lines;
an effluent fluid line in fluid communication with an outlet of the secondary chamber;
at least two further fluid lines selected from a group including
a pre-dilution infusion fluid line in fluid communication with the blood withdrawal line,
a post-dilution infusion fluid line in fluid communication with the blood return line,
a dialysis fluid line in fluid communication with an inlet of the secondary chamber, and
a pre-blood pump infusion fluid line in fluid communication with the blood withdrawal line at a location upstream of the blood pump;
a plurality of fluid pumps configured to pump fluid through said fluid lines; and
a control unit operably connected to said pumps and to a memory, the control unit configured to:
enter in the memory a set value for at least a first fluid flow rate selected from a group of fluid flow rates including
a fluid flow rate Qrep1 through the pre-dilution infusion fluid line,
a fluid flow rate Qrep2 through the post-dilution infusion fluid line,
a fluid flow rate Qpbp through the pre-blood pump infusion fluid line,
a fluid flow rate Qdial through the dialysis fluid line, and
a fluid removal rate Qpfr from the patient,
enter in the memory a set value for a prescribed dose Dset to be delivered,
calculate set values of at least a second and a third of the fluid flow rates of said group of fluid flow rates, based on
said set value for at least a first fluid flow rate entered in the memory,
said prescribed dose value Dset, and
a fluid balance equation establishing that a sum of the fluid flow rates through said pre-dilution infusion fluid line, post-dilution infusion fluid line, dialysis fluid line, and pre-blood pump infusion fluid line shall be equal to a fluid flow rate through the effluent fluid line Qeff,
control one or more of said fluid pumps based on the calculated set values of the fluid flow rates,
verify if a fluid flow rate has been set for at least one of the pre-dilution infusion fluid line or the pre-blood pump infusion fluid line,
calculate a correction factor Fdilution based on the fluid flow rate set for at least one of the pre-dilution infusion fluid line or the pre-blood pump infusion fluid line, and
correct the convective dose flow rate value Dconv_set to account for the effect of pre-dilution based on said correction factor,
wherein said prescribed dose value Dset is a convective dose flow rate value Dconv_set, which is a prescribed mean value of the sum of the fluid flow rates through all infusion fluid lines Qrep1, Qrep2, Qpbp and the patient fluid removal rate Qpfr,
wherein the control unit is configured to correct the convective dose flow rate value to account for the effect of pre-dilution based on said correction factor using the following formula:
Dcorr_conv_set=Fdilution×Dconv_set, where
Fdilution is the correction factor,
Dconv_set is the prescribed mean value of the sum of the fluid flow rates through all infusion fluid lines Qrep1, Qrep2, Qpbp and the patient fluid removal rate Qom, and
Dcorr_conv_set is a corrected convective dose flow rate value, and
wherein the correction factor Fdilution is defined according to one of the following:
a blood dilution factor,
Fdilutionblood=Qblood/Qblood+Qpre,
a plasma dilution factor,
Fdilutionplasma=Qp/Qp+Qpre=(1?Hct)×Qblood/(1?Hct)×Qblood+Qpre, or
a plasma water dilution factor,
Fdilutionpw=Qpw/Qpw+Qpre=(1?Hct)×Fp×Qblood/(1?Hct)×Fp×Qblood+Qpre,
where
Qpre is total a pre-dilution infusion rate set for the pre-dilution infusion fluid line and the pre-blood pump infusion fluid line,
Qblood is a blood flow rate,
Qp is a plasma flow rate,
Qpw is a plasma water flow rate,
Hct is the haematocrit, and
Fp is a plasma water fraction, which is a function of total protein concentration.

US Pat. No. 10,918,775

APPARATUS AND METHOD FOR CARRYING OUT AN ISONATREMIC DIALYSIS

B. BRAUN AVITUM AG, Mels...

1. An apparatus for extracorporeal blood treatment, the apparatus comprising:a dialyzer coupled to a supply line to receive dialysate and to a discharge line to pass the dialysate;
a bypass line coupled between the supply line and the discharge line that bypasses the dialyzer, the bypass line selectively opened during an interposed bypass operation to short circuit the dialyzer with the dialysate remaining in the dialyzer;
a first measuring device configured to measure a variable after the interposed bypass operation from the dialysate that remained in the dialyzer, such that the variable is correlated with a plasma sodium concentration of blood to be cleaned in the dialyzer, the first measuring device downstream of the dialyzer;
a control unit configured to implement the interposed bypass operation with valves to guide the dialysate past the dialyzer with longer and shorter durations so that a residual volume at least partially adopts the concentration of the substances dissolved on a blood side of the dialyzer, to supply the residual volume to the first measuring device for measuring the variable correlated with the plasma sodium concentration of the blood, to configure the first measuring device to measure the conductivity of the residual volume associated with the longer and shorter durations of the bypass operation, and to establish by comparison of the measured results a factor to apply to measurements after the shorter duration to calculate the conductivity of the plasma or plasma water at an inlet of the dialyzer on the basis of measured conductivities of the dialysate in the discharge line before and after the interposed bypass operation; and
a proportioning unit coupled to the control unit, the proportioning unit configured to automatically adjust a composition of the dialysate in the supply line in response to the measured variable and the factor established by the comparison of the measured results to apply to measurements after the shorter duration such that the plasma sodium concentration of the blood at least at an end of the extracorporeal blood treatment has the same value as at a beginning of the extracorporeal blood treatment;
wherein line sections of the supply line and the discharge line located between the bypass line and the dialyzer are pumpless, such that at least at the beginning of the extracorporeal blood treatment the variable correlated with the plasma sodium concentration of the blood is determined during the interposed bypass operation with the dialysate remaining in the dialyzer.

US Pat. No. 10,918,774

HEART ASSIST DEVICE

VADOVATIONS, INC., Oklah...

17. A heart assist device, comprising:a pump housing;
a rotor retained within said pump housing;
said rotor comprising a shaft with an outer surface and an impeller extending from the shaft at a first location on the outer surface at a proximal end of said rotor;
said outer surface comprising an outer bearing surface at a second location on the shaft with a radial bearing at or adjacent to the outer bearing surface; and
an axial bearing comprising a hemispherical surface or conical surface disposed axially adjacent a leakage inlet of said pump housing at a distal end of said rotor;
wherein said axial bearing comprises a plurality of grooves that form a hydrodynamic bearing with a mating surface of the one or more cylindrical bores for opposing axial thrusting of the rotor, while also providing radial stability;
said pump housing comprising two cylindrical bores configured to define a pumping chamber and an inner bearing surface within the pump housing, wherein said pump housing is configured with a first cylindrical bore disposed at a first end of the pump housing, the first cylindrical bore defining an inner bearing surface configured for housing the outer bearing surface of the rotor, and a second cylindrical bore at a second end of the pump housing, the second cylindrical bore configured for housing the impeller;
wherein said axial bearing comprises a plurality of grooves that form a hydrodynamic bearing with a mating surface of the second cylindrical bore for opposing axial thrusting of the rotor while also providing radial stability and promoting blood flow into the leakage flow path from the leakage inlet;
the pump housing further comprising a radial port disposed between the first cylindrical bore and the second cylindrical bore;
wherein, in an operating configuration, the rotor is positioned within the first and second cylindrical bores such that the impeller rotates within the pumping chamber upon actuation of the rotor to draw a first flow of blood inward from a radial port or inlet into the pumping chamber;
wherein rotation of the impeller draws the flow of blood through an axial port disposed at the second end of the pump housing and into the pumping chamber along the length of the second bore to be expelled from the radial port;
wherein said inner bearing surface of the pump housing is closely fitted to said outer bearing surface of said shaft to form an annular clearance there between such that during actuation of the rotor the inner bearing surface and outer bearing surface form a hydrodynamic journal bearing;
wherein the pump housing comprises a leakage inlet in fluid communication with the annular clearance; and
wherein during actuation of the rotor the annular clearance operates as a leakage path to allow a second flow of blood into the leakage inlet, and along the length of the annular clearance between the inner bearing surface and outer bearing surface.

US Pat. No. 10,918,773

COLLAPSIBLE AND SELF-EXPANDING CANNULA FOR A PERCUTANEOUS HEART PUMP AND METHOD OF MANUFACTURING

TCI LLC, St. Paul, MN (U...

1. A collapsible and self-expanding cannula for a percutaneous heart pump, the collapsible and self-expanding cannula comprising:an open proximal end;
an open distal end; and
an elongate, fluid impermissible wall structure; wherein the elongate, fluid impermissible wall structure comprises: (i) a first balloon film disposed on an interior surface of the wall structure and defining a first wall structure circumferential surface; (ii) a second balloon film disposed on an exterior surface of the wall structure and defining a second wall structure circumferential surface; and (iii) a cannula strut disposed between the first balloon film and the second balloon film, wherein the first balloon film, the second balloon film, and the cannula strut are a fused integrated structure having a substantially smooth, continuous inner surface and a substantially smooth, continuous outer surface, wherein a surface layer of the first balloon film comprises a biocompatible first thermoplastic elastomer, and a surface layer of the second balloon film comprises a biocompatible second thermoplastic elastomer.

US Pat. No. 10,918,772

SOLID STATE HEART ASSIST DEVICE

1. A control system comprising:at least one permanent magnet configured to attach to a median septum of a heart;
at leas one electromagnet configured to implant on a wall of the heart to assist the heart to at least one of contract and expand;
an electromagnetic driver configured to control the at least one electromagnet; and
a processor configured to control the electromagnetic driver based on input input received from an electrocardiogram electrode and input from at least one of a blood oxygen sensor, an accelerometer, a blood pressure sensor, an altimeter sensor, and a body temperature sensor.

US Pat. No. 10,918,771

METHODS AND DEVICES FOR APPLYING CLOSED INCISION NEGATIVE PRESSURE WOUND THERAPY

KCI Licensing, Inc., San...

1. A device for treating an incision, the device comprising:a tension relief module, comprising:
a conduit structure forming an internal lumen, the conduit structure comprising:
an upper surface,
a lower surface, and
at least one opening extending through the lower surface and the upper surface, wherein the at least one opening is configured to provide fluid communication between the upper surface of the conduit structure and the incision;
opposing adhesive structures coupled to the conduit structure, wherein the opposing adhesive structures are configured to be manually stretched in a direction perpendicular to the internal lumen from a relaxed configuration to a first tensile configuration to adhere to tissue substantially perpendicular to a length of the incision; and
a flexible sealant structure comprising a lower adhesive surface and configured to cover the tension relief module, wherein the lower adhesive surface of the flexible sealant structure and the upper surface of the conduit structure are configured to form a flow pathway.

US Pat. No. 10,918,770

VACUUM ASSISTED WOUND CLOSURE ASSEMBLY AND METHODS OF IRRADIATING A WOUND USING THE SAME

CORNING INCORPORATED, Co...

1. A method of irradiating a wound, the method comprising:positioning a wound insertion foam within a wound cavity of a wound;
covering the wound insertion foam positioned within the wound cavity using a wound sealing layer comprising a sealing surface, such that the sealing surface seals the wound insertion foam within the wound cavity;
pumping fluid from the wound cavity using a drain tube comprising a drainage end fluidly coupled to the wound insertion foam and sealed within the wound cavity using the wound sealing layer and a vacuum end fluidly coupled to a vacuum source; and
irradiating the wound using a light diffusing optical fiber optically coupled to a therapeutic light source, wherein:
the light diffusing optical fiber comprises one or more light scattering structures distributed along at least a treatment length of the light diffusing optical fiber; and
at least a portion of the treatment length of the light diffusing optical fiber is positioned within a wound tissue region of the wound, the wound cavity, or both, such that at least a portion of light emitted by the therapeutic light source enters the light diffusing optical fiber, scatters outward from the light diffusing optical fiber, and irradiates the wound tissue region, a wound cavity surface of the wound, or both;
wherein a vacuum entry port extends through the wound sealing layer and the drain tube extends into the vacuum entry port such that the drainage end of the drain tube is fluidly coupled to the wound insertion foam; and
wherein the light diffusing optical fiber extends within the drain tube and extends through the vacuum entry port.

US Pat. No. 10,918,769

MEDICAL DRAINAGE DEVICE WITH SQUEEGEE-BASED LUMEN CLEANER AND METHOD OF DRAINING A BIOLOGICAL FLUID FROM THE BODY OF A PATIENT

Boehringer Technologie, L...

1. A drainage device for draining a biological fluid from a body of a patient, said drainage device comprising:a) a drainage tube having a sidewall having a drainage lumen extending therethrough, said drainage lumen has an inner surface, said sidewall including a length, a distal end, a distal end portion located adjacent said distal end and proximally thereof, a proximal end portion, and a longitudinal axis extending said length of said sidewall, said proximal end portion being configured for location outside the body of the patient for coupling to a fluid collection canister, said distal end portion of said drainage tube being configured to be introduced into the body of the patient and including an array of plural apertures in communication with said drainage lumen and configured for receipt of a biological fluid from the body of the patient, said drainage tube additionally comprising a pressure relief lumen extending along said sidewall from a point at said proximal end portion to a pressure relief port located distally of said array of apertures;
b) a pressure relief assembly including a one-way pressure relief valve in communication with said pressure relief port and located within said drainage lumen distally of said array of apertures; and
c) a lumen cleaner assembly including a squeegee unit located in said drainage lumen proximally of said one-way pressure relief assembly and distally of said array of apertures, said squeegee unit being moveable relative to said drainage lumen by a filament located within said drainage lumen, whereupon pulling of a portion of said filament causes said squeegee unit to move in a proximal direction down said drainage lumen to scrape any biological material off said inner surface of said drainage lumen and to carry any biological material scraped off of said inner surface of said drainage lumen to a passageway coupled to said fluid collection canister for collecting said biological material.

US Pat. No. 10,918,767

MAGNETICALLY TEMPLATED TISSUE ENGINEERING SCAFFOLDS AND METHODS OF MAKING AND USING THE MAGNETICALLY TEMPLATED TISSUE ENGINEERING SCAFFOLDS

University of Florida Res...

1. A method of making a biocompatible, tissue scaffold having aligned microchannels, the method comprising:providing a biocompatible precursor material capable of polymerizing or crosslinking to form a gel or solid material upon activation;
providing microparticles comprising one or more magnetic nanoparticles encapsulated in a dissolvable, biocompatible matrix material;
combining the microparticles and the biocompatible precursor material in a mold;
applying a magnetic field to the combined microparticles and biocompatible precursor such that the microparticles spatially align within the biocompatible precursor material forming a plurality of columns of adjacent microparticles, where the columns are substantially directionally aligned with one another;
activating the biocompatible precursor material to crosslink or polymerize such that the biocompatible precursor material substantially solidifies, forming a three dimensional (3D) scaffold around the aligned microparticles;
dissolving the matrix material of the microparticles to produce a plurality of aligned voids and microchannels within the scaffold; and
allowing the dissolved matrix material and the released magnetic nanoparticles to diffuse out of the aligned voids and microchannels within the scaffold.

US Pat. No. 10,918,764

TUNABLE, CONTROLLED-RELEASE, URETHANE-CONTAINING ELASTOMERS AND PROCESSES OF FORMING THE SAME

THE SECANT GROUP, LLC, T...

1. A process of forming an implantable product comprising poly(glycerol sebacate) urethane loaded with an active pharmaceutical ingredient, the process comprising:homogeneously mixing a flowable poly(glycerol sebacate) resin with the active pharmaceutical ingredient and a catalyst to form a resin blend;
selecting an amount of isocyanate such that an isocyanate-to-hydroxyl stoichiometric ratio is in the range of 1:0.25 to 1:1.25;
homogeneously combining the resin blend with the isocyanate to form a reaction mixture; and
injecting the reaction mixture to form the poly(glycerol sebacate) urethane loaded with the active pharmaceutical ingredient
wherein the poly(glycerol sebacate) urethane is loaded with at least 40% w/w of the active pharmaceutical ingredient.

US Pat. No. 10,918,763

COMBINED FULLY ORGANIC HIGH MOLECULAR MATERIAL ARTIFICIAL KNEE JOINT

JIANGSU OKANI MEDICAL TEC...

1. A combined fully organic high molecular material artificial knee joint comprising:a femur condyle;
a tibia liner;
a tibia holder;
wherein the tibia holder comprises a platform and a stable wing positioning portion vertical thereto;
wherein the femur condyle is jointed to an upper end of the tibia liner and the platform of the tibia holder is jointed to a lower end of the tibia liner;
wherein the femur condyle, the tibia holder and the tibia liner are all formed by a high molecular material;
wherein the tibia liner is formed by ultra-high molecular weight polyethylene (UHMWPE); and
wherein each of a left side and a right side of the femur condyle is provided with a groove, and wherein a metal or ceramic inlay matching the shape of the groove is included in the groove.

US Pat. No. 10,918,762

MAGNETIC PANTY LINER ASSEMBLY

16. A magnetic panty liner assembly comprising:a first panel, said first panel being flexible, said first panel being permeable to menstrual fluid, said first panel being elongated rectangularly shaped, said first panel having opposing ends, said opposing ends being arcuate, said first panel comprising foam;
a ridge coupled to and extending from an upper face of said first panel, said ridge being positioned to around a perimeter of said first panel, said ridge being impermeable to menstrual fluid, said ridge comprising plastic;
a second panel coupled to a lower face of said first panel, said second panel being flexible, said second panel being absorbent of menstrual fluid said second panel comprising rayon, said second panel comprising cotton;
a plurality of cylinders coupled to and extending between said lower face of said first panel and a top surface of said second panel, said cylinders being absorbent of menstrual fluid, wherein said cylinders are positioned on said second panel such that each said cylinder is configured for wicking the menstrual fluid from said first panel to said second panel;
a third panel coupled to a bottom surface of said second panel and said perimeter of said first panel such that said second panel is enclosed between said first panel and said third panel, said third panel being flexible, said third panel being impermeable to menstrual fluid, said third panel comprising plastic;
a plurality of magnets fixedly positioned between said third panel and said second panel, said plurality of magnets comprising a strip, said strip being flexible, said strip being magnetic, said strip being rectangularly shaped;
a first slit positioned through said first panel, wherein said first slit is positioned in said first panel such that said first slit is configured for flowing of the menstrual fluid through said first slit positioning said second panel for absorbing the menstrual fluid, said first slit extending extending lengthwise along said first panel;
a coupler coupled to an exterior face of said third panel, said coupler being configured for coupling said third panel to an undergarment of a user, wherein said coupler is positioned on said third panel such that said coupler is configured for coupling said third panel to the undergarment of the user positioning said ridge in abutment to the skin of the user for preventing leakage of the menstrual fluid between said first panel and the skin, such that said first slit is configured for flowing of the menstrual fluid through said first slit positioning said second panel for absorbing the menstrual fluid, such that said magnets are configured for reducing pain from menstrual cramps, said coupler comprising adhesive;
a second slit positioned through said first panel, said second slit being perpendicular to and intersecting said first slit, said second slit being positioned equally distant from said opposing ends of said first panel, wherein said second slit is positioned in said first panel such that said second slit is configured for the flowing of the menstrual fluid through said second slit positioning said second panel for absorbing the menstrual fluid;
a plurality of holes positioned through said first panel, wherein said holes are positioned in said first panel such that said holes are configured for the flowing of the menstrual fluid through said holes for absorbing the menstrual fluid in said second panel, each said hole being positioned between said first slit and said ridge such that said plurality of holes is positioned in a pair of rows, said holes being circularly shaped; and
a plurality of extrusions coupled to and extending from said upper face of said first panel wherein said extrusions are configured for deterring movement of the menstrual fluid along said upper face, each said extrusion being cylindrically shaped, each said extrusion being positioned at an associated said hole.

US Pat. No. 10,918,761

SOLUTION FOR TREATING CONTACT LENS AND CONTACT LENS PACKAGING SYSTEM

PEGAVISION CORPORATION, ...

1. A solution for treating a contact lens, comprising:about 0.01 to about 1.0 parts by weight (pbw) of a polymer having phosphorylcholine groups, a number-average molecular weight of the polymer being about 4,000 to about 1,000,000 daltons, and the polymer consisting essentially of the following structure:

wherein m is a positive integer;
about 0.005 to about 0.05 pbw of a first hydrophilic molecule, a number-average molecular weight of the first hydrophilic molecule being about 10,000 to about 50,000 daltons, and the first hydrophilic molecule being hyaluronic acid (HA) or hyaluronate salt;
about 0.005 to 0.05 pbw of a second hydrophilic molecule, a number-average molecular weight of the second hydrophilic molecule being 100,000 to 400,000 daltons, and the second hydrophilic molecule being hyaluronic acid or hyaluronate salt;
about 0.005 to 0.05 pbw of a third hydrophilic molecule, a number-average molecular weight of the third hydrophilic molecule being 1,000,000 to 5,000,000 daltons, and the third hydrophilic molecule being hyaluronic acid or hyaluronate salt;
about 0.01 to about 1.0 pbw of an inorganic salt; and
about 100 pbw of water.

US Pat. No. 10,918,760

DEODORIZATION MODULE AND STORAGE APPARATUS COMPRISING SAME

Seoul Viosys Co., Ltd., ...

14. A storage apparatus comprising:a storage chamber having an internal space; and
a deodorization module mounted in the storage chamber to deodorize air inside the storage chamber,
wherein the deodorization module comprises:
a housing including a main body and a cover, wherein the main body further includes a bottom surface and side surfaces, and the bottom surface of the housing includes a curved surface that is concave when viewed from an outside of the deodorization module;
a suction hole formed through the bottom surface of the housing to allow air to be drawn into the housing therethrough;
a fan disposed at the suction hole to draw in air;
a discharge hole formed through the bottom surface of the housing to allow the air drawn in by the fan to be discharged from the housing therethrough;
a photocatalyst filter disposed between the fan and the discharge hole and comprising a first through-hole through which the air passes;
a light source module emitting light toward the photocatalyst filter for activating a photocatalytic reaction; and
a fan seating member disposed in an inclined manner at the suction hole and formed with a second through-hole allowing air to be drawn therethrough,
wherein the main body includes an open portion and receiving the fan, the photocatalyst filter, and the light source module,
wherein the cover covers the open portion of the main body, the cover being detachably coupled to the main body,
wherein the fan is seated on the fan seating member,
wherein the suction hole and the discharge hole are formed through the bottom surface of the housing comprising the curved surface,
wherein the air drawn in by the fan passes through the photocatalyst filter before being discharged from the housing through the discharge hole, and
wherein the bottom surface of the housing is entirely curved.

US Pat. No. 10,918,759

AIR PURIFICATION DEVICE

DR. SCHNEIDER KUNSTSTOFFW...

1. An air purification device, comprising a housing having at least one inlet opening for supply of an air flow and at least one outlet opening for discharge of the air flow supplied by way of the at least one inlet opening, wherein at least one air purifying unit and at least one lighting unit are arranged in the housing, wherein the at least one air purifying unit and the at least one lighting unit are arranged opposite one another in the housing, the at least one air purifying unit has at least one photocatalytically active surface region and the air flow is guided in the housing at least partially along the at least one photocatalytically active surface region of the at least one air purifying unit, wherein the at least one photocatalytically active surface region of the at least one air purifying unit can be irradiated with light by the at least one lighting unit and the at least one photocatalytically active surface region is coated at least partly with titanium dioxide or doped with titanium dioxide ions, wherein the at least one air purifying unit comprises two air purifying units arranged opposite one another at inner walls of the housing, wherein the at least one lighting unit is arranged in the housing in the center of the housing to traverse the housing in a plane so that the light emitted by the at least one lighting unit is incident almost in its entirety on the two air purifying units, wherein the at least one photocatalytically active surface region of each of the two air purifying units is shaped with a conical, pleated, cylindrical, frusto-conical, frusto-pyramidal, spherical or hemispherical geometric form or is spiny and the at least one lighting unit is formed as a circuit board, wherein a plurality of light-emitting diodes are arranged in rows and at an equidistant spacing from one another on the circuit board, wherein the rows of the plurality of light-emitting diodes are arranged on an upper side and on a lower side of the circuit board, and wherein air guide elements arranged in the housing and comprising deflectors protruding from the circuit board in an air channel of the housing between the at least one inlet opening and the at least one outlet opening, so that the air flow in the air channel is deflected onto the at least one photocatalytically active surface region of the at least one air purifying unit.

US Pat. No. 10,918,758

MODULAR SELF-CONTAINED DOWNDRAFT VENTILATION SYSTEM TO MITIGATE CROSS CONTAMINATION OF AIRBORNE PATHOGENS

1. A ventilation system to mitigate cross contamination of airborne pathogens within an indoor environment, the system comprising:one or more air handler modules having an inlet plenum fluidly coupled to an airflow urger; and
a plurality of flooring collection modules defining a supporting surface, each flooring collection module having a plurality of airways fluidly connected to the inlet plenum, wherein the airflow urger is configured to induce a low-pressure region across the plurality of airways.

US Pat. No. 10,918,757

DEVICE AND METHOD FOR DIFFUSING DRY FOG

PRESENSIA, Paris (FR)

1. An anti-condensation housing, comprising:a bottle containing a product to be nebulized;
a diffusing head connected to a compressed air inlet communicating with an inside of the bottle to nebulize the product;
a tube comprising a diffusing end, an insufflating end, a bent portion at 90° between the diffusing end and the insufflating end, wherein the, tube has a section with an inscribed circle with a diameter between 60 mm and 120 mm, the section of the tube being continuous and forming a single flow path from the insufflating end to the diffusing end, and over a length between 3 and 10 times the diameter of the inscribed circle, a bending position is configured such that the tube surrounds the bottle and directs an airflow downward at the diffusing head when the bottle is in a vertical position, and a connector to connect the diffusing head to a nebulized product inlet between the diffusing end and insufflating end;
wherein the compressed air inlet is independent from the tube;
an outlet opening at the diffusing end of the tube;
a fan at the insufflating end of the tube, the fan generates an air flow at a flow rate of at least 35 m3 per hour between the insufflating end and the diffusing end of the tube;
a baffle inside the tube, located between the nebulized product inlet and the diffusing end, upstream of the bending position with respect to the air flow, the baffle extending along a direction perpendicular to a direction of the air flow in the tube to provide an obstacle for a progress of the air flow in the tube between the nebulized product inlet and the bent portion, and a height of the baffle is configured to intercept large droplets of the product with a diameter equal to or above 10 ?m and to permit droplets with the diameter below 10 ?m to go through; and
the baffle cooperates with a wall of the tube to create a retention zone in the conduit to retain a nebulized product stopped by the baffle.

US Pat. No. 10,918,755

HOUSING APPARATUS

PHC HOLDINGS CORPORATION,...

1. A housing apparatus for sterilization by irradiation with UV light, the housing apparatus comprising:a UV lamp that radiates the UV light;
an electric wire that supplies power to the UV lamp;
a socket section that supports the UV lamp;
a casing insulated from outside air and inside of which the UV lamp is disposed, wherein
the socket section includes a first opening and a second opening, the first opening being opened toward an interior of the casing, the second opening being in fluid communication with the first opening and being an opening through which the electric wire passes,
the socket section further includes a recessed part that extends axially in a first direction and a protruding part that extends axially in a second direction transverse to the first direction, the recessed part includes the UV lamp, and the protruding part includes the second opening and is received within the casing, and
the casing includes a third opening which guides the electric wire to outside, the third opening being in fluid communication with the second opening; and
a heating section located exterior of the casing,
wherein the heating section at least partially encloses a predetermined length of the electric wire and is configured to heat the electric wire.

US Pat. No. 10,918,754

STERILISATION METHOD

Regeneron Pharmaceuticals...

1. A sterilization method comprising:creating a turbulent flow within a chamber;
while maintaining the turbulent flow, performing a sterilization pulse comprising:
maintaining a sterilization pressure within the chamber of about 400 millibars to about 800 millibars for at least 5 minutes;
introducing vaporized hydrogen peroxide (VHP) into the chamber;
allowing the VHP to circulate within the chamber for at least 5 minutes; and
introducing a first gas into the chamber;
wherein, during the sterilization pulse, condensation forms on at least one surface within the chamber;
halting the turbulent flow within the chamber; and
performing an aeration pulse comprising:
introducing a second gas into the chamber;
maintaining a first aeration pressure in the chamber for at least 5 minutes;
increasing the pressure within the chamber to a second aeration pressure higher than the first aeration pressure; and
exhausting the second gas from the chamber;
wherein the first gas, the second gas, or both comprises nitrogen and/or air, and both the first gas and the second gas have a dew point of ?10° C. or lower.

US Pat. No. 10,918,752

METHOD FOR DISPENSING A FLUID DURING DOOR OPERATION

KleanTouch LLC, Scottsda...

1. A method for dispensing a fluid during an operation of a door handle, the method comprising:in response to a user operating a door handle, actuating a pump to force a fluid disposed in a replaceable fluid container out of the fluid container, into a first end of a flexible tubing, through the flexible tubing to a distribution manifold formed into the flexible tubing at a second end of the flexible tubing, through the distribution manifold via a plurality of self-healing distribution holes, and either onto the door handle or onto a hand of the user.

US Pat. No. 10,918,751

SYSTEMS AND METHOD FOR DECONTAMINATING A TUBE

1. A method for decontaminating a tube, comprising:positioning an antenna at least partially within a tube, wherein the tube is positioned at least partially within a living body; and
decontaminating the tube by causing the antenna to emit electromagnetic waves having a frequency from about 10 GHz to about 100 GHz for a time duration that is less than or equal to 60 seconds, and wherein the electromagnetic waves cause a temperature of the living body proximate to the tube to increase from about 0.1° C. to about 3° C. so as to not substantially damage the living body.

US Pat. No. 10,918,750

PORTABLE LIGHT FASTENING ASSEMBLY

UV Partners, Inc., Grand...

1. A germicidal system for at least partially sterilizing a human interface device including a touch surface, said germicidal system comprising:a housing;
an ultra-violet (UV) light source at least partially enclosed in said housing, wherein said UV light source is configured to project an illumination pattern toward the touch surface of the human interface device;
a sensor configured to detect motion in a monitored area;
a processor for controlling operation of said UV light source, wherein the processor is configured to activate the UV light source to initiate a disinfection cycle of the touch surface between human uses of the human interface device, wherein the processor is configured to activate the UV light source to initiate a periodic disinfection cycle of the touch surface, said processor in communication with said sensor, wherein said processor is configured to receive communication associated with activation of the human interface device;
wherein said processor is configured to deactivate said UV light source in response to motion detection by said sensor; and
wherein said processor is configured to deactivate said UV light source in response to said communication associated with activation of the human interface device.

US Pat. No. 10,918,749

AIRCRAFT CABIN DISINFECTION SYSTEM

Airbus SAS, Bristol (GB)...

1. A cabin disinfection system for an aircraft, the system including:a sensing device configured to sense presence and direction of movement of a person in one or more zones of an aircraft cabin to be disinfected,
one or more ultraviolet C (UVC) radiation sources adapted to disinfect the cabin in the one or more zones; and
a controller configured to control operation of the one or more UVC radiation sources by selecting one or more of the zones to apply UVC radiation to exposed surfaces in the selected one or more zones during the planned disinfection period, wherein the selection is dependent upon whether the sensing device senses the person in the one or more zones and whether the controller predicts, based on data received from the sensing device, that the person will occupy the one or more zones during the planned disinfection period of the selected one or more zones.

US Pat. No. 10,918,748

DEPLOYABLE ULTRAVIOLET LIGHT SANITIZING SYSTEMS AND METHODS

THE BOEING COMPANY, Chic...

1. An ultraviolet (UV) light sanitizing system that is configured to sanitize at least one surface within an enclosed space, the UV light sanitizing system comprising:a UV light assembly that is selectively moveable between a stowed position and a deployed position, wherein the UV light assembly is stowed within a stowage chamber connected to the enclosed space in the stowed position, and wherein the UV light assembly deploys out of the stowage chamber and into the enclosed space in the deployed position,
wherein the UV light assembly is linearly moved between the deployed position and the stowed position.

US Pat. No. 10,918,747

DISINFECTING LIGHTING DEVICE

Vital Vio, Inc., Troy, N...

1. A method for inactivating microorganisms on a surface, the method comprising:emitting, with a first light source, a first light comprising a first correlated color temperature (CCT);
emitting, with a second light source, a second light comprising a second CCT; and
varying respective power levels of the first light source and the second light source such that the first light and the second light combine to form white light comprising:
an intensity associated with light in a 380-420 nanometer (nm) wavelength range sufficient to initiate inactivation of microorganisms on the surface; and
a third CCT between the first CCT and the second CCT.

US Pat. No. 10,918,745

99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN

1. A 99mTc radiolabelled compound having the structure:

US Pat. No. 10,918,744

BIOMETRIC METHOD

Educational foundation Ky...

1. A biometric method including:a step (1) for administering, to a target organism from the outside thereof, one of (i) a target molecule A having both an unpaired electron and a magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of 19F, and (ii) a target molecule B and a radical molecule C, the target molecule B having no unpaired electron, and further having a magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of 19F, the radical molecule C having an unpaired electron; and
a step (2) for causing electron spin resonance in the unpaired electron of the target molecule A or the radical molecule C by irradiating electromagnetic waves to the target organism, subsequently triggering nuclear magnetic resonance in the magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of 19F in one of the target molecule A and the target molecule B, and further, measuring nuclear magnetic resonance signals,
the step (2) being carried out in a magnetic field having such an intensity that the nuclear magnetic resonance signals of the magnetic resonance nucleus in one of the target molecule A and the target molecule B are degenerated, the magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of 19F.

US Pat. No. 10,918,743

CONTRAST MEDIUM FORMULATION AND RELATED PREPARATION METHOD

GUERBET, Villepinte (FR)...

1. A liquid pharmaceutical composition comprising a complex of formula (I):
in which R1, R2 and R3 represent —COOH,
X1, X2 and X3 represent, independently of one another, L-Y in which L represents (CH2)n with n=1 to 3, and Y represents —CONH2, —CO—NR7R8 or —NR7—CO—R8, in which R7 represents H or a C1-C6 alkyl group or a C1-C6 hydroxyalkyl group, and R8 represents a C1-C6 alkyl or C1-C6 hydroxyalkyl group, provided that at least R7 or R8 represents a C1-C6 hydroxyalkyl group;
D represents CH;
E represents N;
Fi represents CH;
K1 to K12 each independently represent H; and
M represents Gd3+;
or an enantiomer or a diastereoisomer;
wherein said composition also comprises a calcium complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA);
wherein M complexed with DOTA is more thermodynamically stable than M complexed in formula (I);
wherein said composition has a concentration of free paramagnetic metal of less than 1 ppm (m/v);
wherein a concentration of said complex of formula (I) comprised between 0.001 and 1.5 mol·l?1; and
wherein a proportion of DOTA-Ca is from 0.01% to 5% mol/mol, with respect to the proportion of complex of formula (I) in said composition.

US Pat. No. 10,918,742

IODINE-BASED PARTICLES

NANOPROBES, INC., Yaphan...

1. An iodine nanoparticle which is a reaction product of functionalized triiodobenzene, a linking monomer, and a biocompatible polymer;wherein said functionalized triiodobenzene, said linking monomer, and said biocompatible polymer are covalently cross-linked resulting in the structure of said nanoparticle being non-dendritic, non-uniform, and non-linear;
wherein the reaction product is not a dimer;
wherein said nanoparticle has sufficient iodine density to be imaged by an imaging device following administration to a subject;
wherein said nanoparticle provides for an extended blood half-life of at least 6 hours,
wherein:
said functionalized triiodobenzene is functionalized 1,3,5-triiodobenzene or functionalized 2,4,6-triiodobenzene,
said linking monomer is carbohydrazide,
said biocompatible polymer is polyethyleneglycol-amine, and
wherein said nanoparticle comprises the structure:

US Pat. No. 10,918,741

PSMA-TARGETING IMAGING AGENTS

THE CLEVELAND CLINIC FOUN...

1. A PSMA-specific imaging agent comprising a compound according to formula I:
wherein the agent is selected from the group consisting of E?E-Amc-Ahx-dEdEdEGYGGGC-NH2 (SEQ ID NO: 7), E?E-Amc-Ahx-dEdEdEYK(Bn-NOTA)-NH2 (SEQ ID NO: 8), and E?E-Ahx-EEEYK(Bn-NOTA)-NH2 (SEQ ID NO: 9), and pharmaceutically acceptable salt thereof.

US Pat. No. 10,918,739

SDR5-FC FUSION PROTEIN MUTANT AND USE THEREOF

Suzhou Yongxin Biological...

1. A fusion protein consisting of a sDR5 fragment and a Fc fragment of a human antibody; wherein the amino acid sequence of the sDR5 fragment isthe amino acid sequence shown in SEQ ID NUMBER 1; and
wherein the amino acid sequence of the Fc fragment of human antibody is any one of the following group:
(1) the amino acid sequence shown in SEQ ID NUMBER 2; and
(2) the amino acid sequence obtained by replacing Asp at position 50 with Ala in the amino acid sequence shown in SEQ ID NUMBER 2.

US Pat. No. 10,918,735

SUBSTITUTED PYRAZINO[1?,2?:1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT

Massachusetts Institute o...

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 1, or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,918,734

TREATMENT OF HIGH TROP-2 EXPRESSING TRIPLE NEGATIVE BREAST CANCER (TNBC) WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES HOMOLOGOUS RECOMBINATION REPAIR (HRR) RESCUE MEDIATED BY RAD51

Immunomedics, Inc., Morr...

1. A method of treating a Trop-2 expressing cancer comprising:a) administering to a subject with a Trop-2 expressing cancer an anti-Trop-2 antibody-drug conjugate (ADC), wherein the drug is SN-38 and the antibody is a humanized RS7 antibody comprising the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO:1), CDR2 (SASYRYT, SEQ ID NO:2), and CDR3 (QQHYITPLT, SEQ ID NO:3) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4), CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO:5) and CDR3 (GGFGSSYWYFDV, SEQ ID NO:6); and
b) administering to the subject an inhibitor of Rad51 selected from B02 ((E)-3-benzyl-2(2-(pyridin-3-yl)vinyl) quinazolin-4(3H)-one) and RI-1 (3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione).

US Pat. No. 10,918,733

LIPOPEPTIDE- AND LIPOPROTEIN-CONJUGATES AND ITS USE

HELMHOLTZ-ZENTRUM FUER IN...

1. Lipopeptide-compound or lipoprotein-compound according to formula I, or lipopeptide-conjugate or a lipoprotein-conjugate according to formula I, having an adjuvant moiety, a first antigen moiety, a second antigen moiety and, optionally, a conjugate moiety:
wherein R1 and R2 can be identical or different and are selected from C11-C17 alkyl or C11-C17 alkenyl groups;
R3 and R4 can be identical or different and are selected from hydrogen or C1-6 Alkyl group;
X is S;
Y1 represents a first antigen moiety recognized by a CD4+ T cell and Y2 represents a second antigen moiety recognized by a CD8+ T cell, or vice versa, wherein the size for the CD8+ T cell-recognized antigen moiety is of from 8 to 14 and for the CD4+ T cell-recognized antigen moiety is of from 10 to 20 amino acid residues and wherein Y1 and Y2 represent antigenic epitopes from at least one microorganism causing a parasitic or infectious disease selected from the group consisting of hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS), Dengue fever, influenza, Helicobacter pylori infection, herpesvirus infection, tuberculosis, leprosy, listeriosis, malaria, and Tryopanosoma cruzii infection, and
L is an amino acid sequence of 1 to 3 amino acid residues;
R5 is hydrogen or a covalently linked conjugate moiety comprising polyalkylene glycol units of the formula II
Z1—[(CHR6)n—O)]x—(CH2)2—Z2  (II)
where Z1 is a hydrocarbon or a NR3 group whereby R3 is defined as above, R6 is independently any one of hydrogen, OH, C1-6 alkyl group, OR7 or COR8;
R7 is independently any one of hydrogen or C1-6 alkyl group;
R8 is independently any one of hydrogen, OH, OR7 or NR9R10;
R9 and R10 are independently any one of hydrogen or hydrocarbon which may contain heteroatom (s) and which may form a ring;
x is an integer of 1 to 100;
n is independently an integer of 1 to 10; and
Z2 is a hydrogen or a hydrocarbon which may contain heteroatom(s);wherein Y1-L-Y2 of Formula I, comprising the antigen moieties, has the sequence identity of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, orwherein Y1 is an Ig-like domain EIII of a flavovirus envelope glycoprotein E and Y2 is SEQ ID NO:5.

US Pat. No. 10,918,728

COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM

IMBRIA PHARMACEUTICALS, I...

1. A pharmaceutical composition comprising a controlled-release formulation of a compound represented by formula (X):

US Pat. No. 10,918,726

CARBOSILANE DENDRIMER AND AGGREGATABLE CARRIER OBTAINED USING SAID DENDRIMER FOR DRUG DELIVERY SYSTEM

Saitama University, Sait...

1. An aggregatable carrier material for a drug delivery system comprising an aggregatable dendrimer compound shown in formula (I):[Chemical formula 1]
R1[(R2—Si)(—R3—Y)3]2  (I)
wherein in the formula (I), R1 is silole group shown in the following formula (II); each of R2 and R3 is a hydrocarbon chain having 1 to 6 carbon atoms which may have the same or a different hydrocarbon chain or a ring; Y is a halogen group or a targeted sequence presented part (TSPP) bound via a sulfur atom wherein at least one of Y is a TSPP; and

wherein R is a phenyl group; and n is 4 in the formula (II);
wherein the targeted sequence presented part (TSPP) comprises a protein having a targeted recognition site of which said sulfur atom in said protein is located outside the folded protein; and
wherein said targeted sequence presented part aggregates in an aqueous solvent to form a micelle having the diameter from 50 to 500 nm, and when said aggregatable molecule aggregates, said aggregated micelles emit fluorescence.

US Pat. No. 10,918,720

SELECTIVE DENDRIMER DELIVERY TO BRAIN TUMORS

THE JOHNS HOPKINS UNIVERS...

1. A method of treating a brain tumor comprising systemically administering to a subject having a brain tumor a composition comprisingpoly(amidoamine) (PAMAM) hydroxyl-terminated dendrimers selected from the group consisting of generation 4 generation 5, generation 6, generation 7, generation 8, generation 9, and generation 10 PAMAM dendrimers, covalently linked to or complexed with one or more modulators of tumor immune response,
wherein the dendrimers are not conjugated to targeting moieties,
wherein the hydrodynamic diameter of the dendrimers covalently linked to or complexed with the modulators is less than 10 nm, have a surface charge of about zero, and
wherein the composition is in a dosage effective to suppress or inhibit the growth of the brain tumor in the brain of the subject.

US Pat. No. 10,918,719

METHODS FOR CROSS-LINKING CORNEAL COLLAGEN WITH VERTEPORFIN FOR THE TREATMENT OF DISORDERS OF THE EYE

Massachusetts Eye and Ear...

1. A method for increasing corneal rigidity in a subject, comprising:identifying a subject who has keratoconus, pellucid marginal degeneration, post-operative ectasia or who has refractive defects and plans to undergo a refractive surgical procedure at a later time;
topically administering an effective amount of a composition comprising verteporfin to the cornea of the subject; and
irradiating the cornea with non-thermal laser light with a wavelength of 687 nm to 693 nm, wherein the administering and irradiating steps are repeated for a total of at least six times,
wherein the irradiating step comprises continuous exposure to non-thermal laser light for 30 to 60 seconds in duration, and targeting the non-thermal laser light to a depth within the cornea in a range of 50 microns to 500 microns.

US Pat. No. 10,918,717

PHARMACEUTICAL FORMULATION COMPRISING ANTI-EGFR ANTIBODY

GREEN CROSS CORPORATION, ...

1. A pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody, sodium acetate anhydrous, and polysorbate 80, wherein the anti-EGFR antibody is comprised in a concentration of 2 to 10 mg/ml,wherein the anti-EGFR antibody is GC1118A;
wherein the sodium acetate anhydrous is comprised in a concentration of 50 to 100 mM;
wherein no sodium chloride (NaCl) is included in the pharmaceutical formulation; and
wherein the pharmaceutical formulation shows a greater stability compared to a same pharmaceutical composition except for comprising sodium chloride under storage conditions of 60° C. for two weeks; and
wherein the pH of the pharmaceutical formulation ranges from pH 5.3 to 6.1.

US Pat. No. 10,918,714

HUMAN INKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS

ACADEMIA SINICA, Taipei ...

1. An immune adjuvant compound having Formula (I):or a pharmaceutically acceptable salt thereof;wherein:R1 is —OH or halogen;
R2 is —OH;
R3 is hydrogen;
each instance of R4 and R5 is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted alkoxy, an optionally substituted amino group, or optionally substituted acyl;
n is an integer of 5 to 15, inclusive;
m is an integer of 1 to 20, inclusive.

US Pat. No. 10,918,709

IMMUNE MODULATOR AND VACCINE COMPOSITION CONTAINING THE SAME

EYEGENE INC., Seoul (KR)...

1. An immune modulator represented by the following Formula 1:
wherein Glc is glucose, GlcN is glucosamine, HEP is heptose, KDO is 2-keto-3-deoxy-octonate, GlcNAc is N-acetylglucosamine, P is phosphate, and C to E are positions to which phosphates can be bonded, wherein each phosphate is bonded at a position selected from the group consisting of C, E, CD, CE, DE, and CDE of Formula 1,
wherein the immune modulator is detoxified by deacylating lipid A through treatment of lipooligosaccharide (LOS) with an alkali.

US Pat. No. 10,918,707

VIRB10 FOR VACCINATION AGAINST GRAM NEGATIVE BACTERIA

University of Florida Res...

1. A method of immunizing a host against an infection by a bacterium having Type 4 secretory system (T4SS), the method comprising administering an effective amount to the host an immunogenic composition comprising an immunological Iv effective amount of a T4SS protein conjugated to a carrier protein and a pharmaceutically acceptable carrier and/or an adjuvant; wherein the T4SS protein consists of VirB10 of Anaylasma phagocytophilum, and wherein the bacterium is Anaplasma phagocytophilum.

US Pat. No. 10,918,703

FUSION PROTEINS FOR TREATING INFLAMMATORY DISEASES

The Regents of the Univer...

1. A fusion protein comprising a secretory signal peptide, an elafin region, a linker, and a Fc region, wherein the fusion protein comprises one or more point mutations in the elafin region relative to SEQ ID NO:1 selected from the group consisting of V5G, V9G, M25L, and M51V, and wherein one of the point mutations is selected from the group consisting of M25L and M51V.

US Pat. No. 10,918,697

CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION

1. A method of treating a subject for a neuronal lesion, comprising:administering to the subject a therapeutically effective amount of an inhibitor of phosphatase and tensin homolog (PTEN) and a therapeutically effective amount of an inhibitor of suppressor of cytokine signaling 3 (SOCS3), wherein administering results in contacting one or more target neurons of the subject with the inhibitor of PTEN and the inhibitor of SOCS3, to thereby promote sustained survival, sustained regeneration, sustained compensatory outgrowth, or a combination thereof in the target neurons.

US Pat. No. 10,918,690

APPARATUS AND METHOD FOR PROCESSING ORGANIC BAMBOO LEAF EXTRACT PRODUCTS

1. A method, comprising:harvesting bamboo leaves from a bamboo forest;
using hot air to sterilize the bamboo leaves in a step for drying the harvested bamboo leaves;
shredding and packing the dry bamboo leaves;
mixing sterilized water steam vapor and the shredded dry bamboo leaves for extracting a dry bamboo leaves essence into a bamboo leaf extract condensate;
filtering the bamboo leaf condensate;
mixing in purified water with the filtered bamboo leaf condensate;
creating bamboo leaf extract based products from the mixed, filtered bamboo leaf condensate selected from the group consisting of bottled beverages, cosmetics, pharmaceuticals, foods, food additives and dietary supplements; and
packaging the created bamboo leaf extract based products.

US Pat. No. 10,918,687

KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

Kuality Herbceutics LLC, ...

1. A method for treating cancer, preventing cancer, preventing tumorigenesis, reducing DNA damage, reducing protein damage, detoxifying physical carcinogens, and/or detoxifying chemical carcinogens in a mammal in need of such treatment comprising, administering to the mammal a composition comprising 11-methoxyyangonin, flavanone:anddihydromethysticin, wherein the composition comprises less than 0.3% by weight of a bornyl ester of cinnamic acid of the formula:

comprises less than 0.3% by weight of flavokawain B; and comprises less than 0.3% by weight of flavokawain A.

US Pat. No. 10,918,680

PHAGE THERAPY OF E COLI INFECTIONS

PHERECYDES PHARMA, Romai...

1. A method of treating of an infection in a mammal in need thereof, comprising administering to the mammal infected with an Escherichia coli (E. coli) strain an antibacterial composition in an amount effective to treat said E. coli infection, wherein said composition comprises at least two distinct bacteriophages having lytic activity to said E. coli strain, said at least two distinct bacteriophages being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs: 1 to 15 or a sequence having at least 99% identity thereto.

US Pat. No. 10,918,675

WATER RESISTANT ENHANCED WOUND HEALING FILM AND PREPARATION METHOD THEREOF

HUAZHONG AGRICULTURAL UNI...

1. A water resistant enhanced wound healing which comprises components by mass to volume at concentrations of:(i) ultra-fine eggshell powder—5-10 mg/L;
(ii) shell membrane soluble protein—50-500 mg/L;
(iii) lysozyme—5-30 mg/L;
(iv) chitosan—5-10 mg/L;
(v) glycerin—0.05-5 mg/L, and
(vi) a polysaccharide polymer—0.1-5 mg/L.

US Pat. No. 10,918,662

STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE

Exela Pharma Sciences, LL...

1. A solution of L-cysteine comprising,a pharmaceutically acceptable carrier, and
about 50 mg/mL of L-cysteine hydrochloride monohydrate, or
equivalent amount of a pharmaceutically acceptable L-cysteine or a salt or hydrate thereof;
wherein the solution is stored in a single-use vial;
wherein for at least 12 months from the time of manufacture of the solution, the solution will remain:
substantially free of visually detectable particulate matter,
at a pH from about 1.0 to 2.5, and
containing no more than 50 ppb of aluminum; and
wherein the solution is safe for use as an additive in a parenteral nutrition composition for intravenous administration to an individual for at least 12 months from the time of manufacture of the solution.

US Pat. No. 10,918,657

TREATMENT OF SPINAL CORD INJURY OR TRAUMATIC BRAIN INJURY BY INHIBITION OF SYNUCLEIN PROTEIN AGGREGATION

The Regents of the Univer...

1. A method of treating a subject having a spinal cord injury, said method comprising administering to said subject a molecular tweezers comprising the structure of CLRO1:
wherein said molecular tweezers inhibits aggregation of synuclein protein in an amount sufficient to reduce aggregation and resulting cytotoxicity of said synuclein protein.

US Pat. No. 10,918,648

ESTROGEN RECEPTOR MODULATOR COMBINATIONS

The Regents of the Univer...

1. A method of treating breast cancer associated with estrogen receptor activity in a patient in need thereof, the method comprising administering to the patient an effective amount of:(i) a CDK 4/6 inhibitor selected from the group consisting of palbociclib, ribociclib, and abemaciclib; and
(ii) a compound of formula:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,918,647

SELECTIVE BROMODOMAIN INHIBITION OF FUNGAL BDF1

University of Southern Ca...

1. A compound selected from the group consisting of MS4 and MS5:

US Pat. No. 10,918,645

SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF

LIFEARC, London (GB)

1. A compound of formula I, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof:
wherein:
V is N;
W is N;
R1 is selected from the following groups:

X1 is CO or —(CH2)n—;
Y is

wherein
Q5 is N optionally substituted with one or more substituents chosen from C1-6 alkyl, C3-7 cycloalkyl, C3-7 heterocycloalkyl, F, Cl, Br, I, —NO2, —CN, —N3, —NH2, —OH or C1-6 haloalkyl;
Q6 is N;
Q7 is CH;
Z is a bond;
n is 1;
R2 and R3 are independently selected from —H, C1-6 alkyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, C6-14 aryl or C1-10 heteroaryl, wherein each of said C1-6 alkyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, C6-14 aryl and C1-10 heteroaryl is optionally and independently substituted with one or more substituents chosen from F, Cl, Br, I, —NO2, —CN, —N3, —NH2, —OH, and —CO2H.

US Pat. No. 10,918,642

N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS

Nerviano Medical Sciences...

1. A process for preparing a compound of formula (I)
wherein
n is 0, 1 or 2;
R1 is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl;
R2 and R3 are independently halogen, cyano, OR4 or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl, wherein
R4 is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl;
E1 and E2 are independently CH or N;
A is O, S or NR5, wherein
R5 is hydrogen or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl;
or a pharmaceutically acceptable salt thereof, which comprises the step of cross-coupling of an intermediate of formula (II)

wherein E1 and E2 are independently CH or N;
A is O, S or NR5, wherein
R5 is hydrogen or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8) cycloalkyl, (C3-C8) cycloalkenyl, heterocyclyl, aryl and heteroaryl; and
X is halogen or a leaving group, alternatively with the following compounds:
Step a) a derivative of formula (IV)

wherein R2 and R3 are independently halogen, cyano, OR4 or an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl, wherein
R4 is an optionally substituted group selected from straight or branched (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl and (C3-C8) cycloalkyl;
n is 0, 1 or 2;
M is an organometal group and Pg is a nitrogen protecting group; followed by
Step e) selective removing of the Pg group from the resultant intermediate of formula (V)

wherein E1, E2, A, R2, R3, n and Pg are as defined above; and
Step f) reacting the resultant intermediate of formula (VII)

wherein E1, E2, A, R2, R3 and n are as defined above, with a derivative of formula (XI)

wherein R1 is as defined above, to obtain a compound of formula (I)

as defined above;
OR:
Step b) a derivative of formula (VI)

wherein R2, R3, n and M are as defined above; followed by
Step f) reacting the resultant intermediate of formula (VII), as defined above, with a derivative of formula (XI), as defined above, to obtain a compound of formula (I)

as defined above;
OR:
Step c) a derivative of formula (VIII)

wherein R1, R2, R3, n and M are as defined above;
OR:
Step d) a derivative of formula (IX)

wherein R1, R2, R3, n, Pg and M are as defined above; followed by:
Step g) selective removing of the Pg group from the resultant intermediate of formula (X)

wherein E1, E2, A, R1, R2, R3, n and Pg are as defined above, to obtain a compound of formula (I)

as defined in claim above;
optionally converting said compound of formula (I) into another compound of formula (I), converting said compound of formula (I) into a pharmaceutically acceptable salt thereof, or converting said salt into a free compound (I).

US Pat. No. 10,918,641

USE OF MTAP INHIBITORS FOR THE TREATMENT OF LUNG DISEASE

The University of North C...

1. A method of inhibiting inflammation in the lungs of a subject having a lung disease associated with inflammation, comprising administering to the subject an effective amount of a transition state MTAP inhibitor, thereby inhibiting inflammation in the lungs of the subject;wherein the lung disease associated with inflammation is cystic fibrosis (CF), chronic obstructive pulmonary disorder (COPD), asthma, acute or chronic bronchitis, primary ciliary dyskinesia, bronchiectasis, acute respiratory distress syndrome, or any combination thereof; and
wherein the MTAP inhibitor is:
(a) methylthio-DADMe-Immucillin-A (MTDIA);
(b) a compound of formula (I):

wherein
X is alkyl, cycloalkyl alkenyl, alkynyl, or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, alkoxy, cycloalkyl, thiol, alkylthio, arylthio, aralkylthio, halogen, carboxylic acid, carboxylate alkyl ester, nitro, cyano, thiazole, or NR2R3, wherein each alkylthio, arylthio and aralkylthio is optionally substituted with one or more alkyl, halogen, amino, hydroxy, or alkoxy, or
X is SR1; or
X is NR2R3;
R1, R2 and R3 are independently selected from alkyl, alkenyl, alkynyl, aralkyl, or aryl, each of which is optionally substituted with one or more substituents selected from hydroxy, alkoxy, thiol, alkylthio, arylthio, aralkylthio, halogen, carboxylic acid, carboxylate alkyl ester, nitro, cyano or NR2R3, wherein each alkylthio, arylthio, and aralkylthio is optionally substituted with one or more alkyl halogen, amino, hydroxy, or alkoxy;
A is N or CH;
B is NH2 or NHR4;
R4 is alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynvl, or aryl, each of which is optionally substituted with one or more halogen or hydroxyl; and
D is H, OH, NH2, or SCH3;
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester prodrug form thereof;
provided that when B is NH2, D is H and A is CH, X is not propyl, phenylethyl, CH2SQ, CH2OH, or CH2OQ, wherein Q is optionally substituted alkyl, aralkyl, or aryl;
(c) a compound of formula (II):

wherein
W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ;
Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q;
Q is alkyl, aralkyl, or aryl, each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy;
R1 is a radical of formula (III):

or
R1 is a radical of formula (IV):

A is selected from N, CH and CR2;
R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 or SR5;
R3, R4, and R5 are each independently alkyl, aralkyl, or aryl optionally substituted with hydroxyl or halogen, and
wherein R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl;
B is selected from hydroxy, NH2, NHR6, SH, hydrogen, or halogen;
R6 is alkyl, aralkyl, or aryl optionally substituted with hydroxy or halogen;
D is selected from hydroxy, NH2, NHR7, hydrogen, halogen, or SCH3;
R7 is alkyl, aralkyl, or awl group optionally substituted with hydroxy or halogen;
E is selected from N and CH;
G is C1-4 saturated or unsaturated alkyl optionally substituted with hydroxy or halogen, or G is absent;
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof;
(d) a compound of formula (V):

wherein
R1 is H or NR3R4;
R2 is H or alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, or aryl each of which is optionally substituted with one or more hydroxy, alkoxy, thiol, alkylthio, arylthio, aralkylthio, halogen, carboxylic acid, carboxylate alkyl ester, nitro, or NR3R4, wherein each alkylthio, arylthio, and aralkylthio group is optionally substituted with one or more alkyl, halogen, amino, hydroxy, or alkoxy;
provided that when R1 is H, R2 is alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, or aryl which is substituted with at least one NR3R4;
R3 and R4, independently of each other, are H or is alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, or aryl each of which is optionally substituted with one or more hydroxy, alkoxy, thiol, alkylthio, arylthio, aralkylthio, halogen, carboxylic acid, carboxylate alkyl ester, nitro, or NR3R4, wherein each alkylthio, arylthio and aralkylthio group is optionally substituted with one or more alkyl, halogen, amino, hydroxy, or alkoxy;
A is N or CH;
B is OH or alkoxy; and
D is H, OH, NH2, or SCH3;
provided that when R1 is NR3R4, R2 is H, A is CH, B is OH, and D is H, then R3 is not hydroxyethyl or hydroxypropyl when R4 is hydroxyethyl; and
provided that when R1 is NR3R4, R2 is H, A is CH, B is OH, and D is NH2, then R3 is not hydroxyethyl when R4 is H, methyl, ethyl, or hydroxyethyl, and R4 is not hydroxyethyl when R3 is H, methyl, ethyl, or hydroxyethyl;
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester prodrug form thereof; or
(e) a compound of formula (VI):

where A is N or CH: B is OH or alkoxy; and D is H, OH, NH2 or SCH3.

US Pat. No. 10,918,640

AZETIDINE DERIVATIVES

1. A process for forming a compound of Formula (I)comprising the step of reacting a compound of formula (IVa) with a boronic acid of formula (IVb) or a boronic ester thereof to form the compound of Formula (I)whereinAr1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms;
Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring;
Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms; and
X is I or Br.

US Pat. No. 10,918,639

COMBINATION CONTAINING SGC STIMULATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS

BAYER PHARMA AKTIENGESELL...

1. A combination comprising (methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate) of the formula (X)
and (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide of the formula (IV)

US Pat. No. 10,918,637

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Aptinyx Inc., Evanston, ...

1. A compound represented by:or a pharmaceutically acceptable salt and/or stereoisomer thereof, wherein:X is O or NR2;
R1 is selected from the group consisting of H, C1-C6alkyl, phenyl, —C(O)—C1-C6alkyl, and —C(O)—O—C1-C6 alkyl;
R2 is selected from the group consisting of H, C1-C6alkyl, phenyl, —C(O)—C1-C6alkyl, and —C(O)—O—C1-C6 alkyl;
p is 1;
R5 is independently selected for each occurrence from the group consisting of H, C1-C6alkyl, —S(O)w—C1-C3alkyl, —NRaRb, C1-C3alkoxy, cyano and halogen;
w is 0, 1, or 2;
R3 is selected from the group consisting of H, C1-C6 alkyl, phenyl, —C(O)R31 and —C(O)OR32;
R31 and R32 are each independently selected from the group consisting of H, C1-C6alkyl, —C3-C6cycloalkyl, and phenyl; and
R7 is independently selected for each occurrence from the group consisting of H, halogen, phenyl, and C1-C6 alkyl; and
Ra and Rb are each independently for each occurrence selected from the group consisting of H, C1-C3alkyl, and phenyl, or Ra and Rb taken together with the nitrogen to which they are attached form a 4-6 membered heterocyclic ring;
wherein any aforementioned C1-C6 alkyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from —C(O)NRaRb, —NRaRb, hydroxyl, S(O)w—C1-C3alkyl, SH, phenyl and halogen, and any aforementioned phenyl, independently for each occurrence, is optionally substituted by one, two or three substituents each independently selected from hydroxyl, halogen, —C(O)—O—C1-C3alkyl, —C(O)—C1-C3alkyl, methyl, and CF3.

US Pat. No. 10,918,636

DEVICE AND KIT FOR DOSING AND DISPENSING NON-LIQUID MEDICINE

AMPLIPHARM PHARMACEUTICAL...

1. A kit comprising:a device for dosing and dispensing a dose of a non-liquid medicine contained in a container, the device comprising:
a body comprising a first chamber of a first predetermined size and configured to contain the non-liquid medicine, the body having an outer wall, a first part of which is shared with the first chamber, a first slot being defined through the first part of the outer wall of the body shared with the first chamber;
a first plunger rod located in the first chamber, the first plunger rod having a first dose tab that extends outside of the first chamber through the first slot, the first dose tab being usable to move the first plunger rod within the first chamber to vary the first predetermined size to set the dose of the non-liquid medicine; and
a coupling connected with the body and being sized and shaped to removably connect the body with the container, the coupling having a first aperture, at least one of the coupling and the body being rotatable between a first position, in which the first aperture is at least partially aligned with the first chamber, and a second position, in which the first aperture is not aligned with the first chamber; and
a non-liquid medicine that is readily dispersible in an aqueous solution suitable for oral administration.

US Pat. No. 10,918,628

TREATMENT OF SYNUCLEINOPATHIES

1. A method for treating a synucleinopathy in a human or non-human animal in need thereof, comprising:administering a compound to said human or said non-human animal,
wherein the compound is a PDE1A modulator and/or a PDE1C modulator,
wherein the compound is represented by the following formula (I):

wherein
R1 is halo,
a is 0, 1, 2, or 3,
R2 is selected from the group consisting of —H and —(C1-C6)alkyl,
R3 and R4 are independently selected from the group consisting of —H, —OH, —(C1-C6)alkyl, and —(C1-C6)-hydroxyalkyl, or
R3 and R4 taken together are ?O, or
R2 and R3 together with the nitrogen atom and carbon atom they are attached to form a 6-membered heterocyclic ring which is optionally substituted,
R5 and R6 are independently selected from the group consisting of —H and —(C1-C6)alkyl, or
R5 and R6 taken together form a carbon-carbon bond,
or a pharmaceutically acceptable salt thereof,
wherein the alkyl and hydroxyalkyl groups are optionally substituted,
wherein the synucleinopathy is multiple system atrophy (MSA), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), rapid eye movement sleep behavior disorder (RBD), or synucleinopathies caused by mutations in genes other than SNCA.

US Pat. No. 10,918,627

CONVERGENT AND ENANTIOSELECTIVE TOTAL SYNTHESIS OF COMMUNESIN ANALOGS

Massachusetts Institute o...

10. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

US Pat. No. 10,918,626

METHOD FOR IMPROVING PHARMACOKINETICS

Roche Palo Alto LLC, Sou...

1. A method of treating a Hepatitis C virus infection in a patient in need thereof comprising
administering the compound of formula I as a free base or a pharmaceutically acceptable salt thereof and ritonavir wherein the dose of ritonavir is 50 to 400 ma/day and the dose of compound I was 25 to 600 ma/day.

US Pat. No. 10,918,625

USE OF SESQUITERPENE DERIVATIVE

KOOKMIN UNIVERSITY INDUST...

1. A method for treating macular degeneration or macular edema, comprising administering to a mammal in need thereof a pharmaceutical composition comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein the broken line denotes a single bond or a double bond, and
wherein:
i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; or
iii) if the bond between C-5 and C-6 is a double bond, R1 is absent and the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
R1 is H or CH3,
R3 is a functional group selected from a group consisting of R3a through R3d,

in R3a,
i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
ii) R5 is COOCH3, R7 is H or OH, R8 is OH and R4 and R6 are H,
in R3b,
R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,

in R3c,
each of R11 and R12 is OH or OAc and R13 is H; or
each of R11 and R12 is OH or OCH3 and R13 is CH3 and
in R3d,
R14 is OCH3 and R15 and R16 are CH3.

US Pat. No. 10,918,624

ANTI-CANCER AZOLE COMPOUNDS

Imam Abdulrahman Bin Fais...

1. A compound having the chemical structure of formula I:
wherein the azole is selected from the group consisting of:
wherein R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are independently selected from the group consisting of a hydrogen, NR12R13, OR12, SR12, SeR12, an optionally substituted alkyl, an optionally substituted alkylene, an optionally substituted cycloalkyl, an optionally substituted aryl, and an optionally substituted arylalkyl; and R12 and R13 are independently hydrogen, an optionally substituted alkyl, an optionally cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, and an optionally substituted arylalkyl; or R2 and R3, R7 and R8, or R9 and R10 are linked together forming an optionally substituted ring selected from the group consisting of a five membered ring, a six membered ring, a seven membered ring, or an eight membered ring.

US Pat. No. 10,918,623

METHODS OF TREATING INFLUENZA

Biotron Limited, Sydney ...

1. A method for inhibition of an influenza virus infection by the influenza virus in a subject, the method comprising administering to the subject an effective amount of N-carbamimidoyl-5-(1-methyl-iH-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, wherein the administering inhibits replication of the influenza virus in the subject.

US Pat. No. 10,918,622

COMPOUNDS USEFUL AS KINASE INHIBITORS

Loxo Oncology, Inc., Ind...

1. A method of treating B-cell non-Hodgkin lymphoma, wherein the method comprises administering a therapeutic amount of a compound of the formula:
or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

US Pat. No. 10,918,621

ENALAPRIL FORMULATIONS

SILVERGATE PHARMACEUTICAL...

1. A stable oral liquid formulation, consisting essentially of:(i) about 0.6 to about 1.2 mg/ml enalapril or a pharmaceutically acceptable salt or solvate thereof;
(ii) a buffer to maintain the pH about 4.5 or below, wherein the buffer concentration is about 5 mM to about 20 mM;
(iii) a preservative, wherein the preservative is a paraben or a mixture of parabens; and
(iv) water;
wherein the formulation optionally comprises a sweetener, a flavoring agent, or both;
wherein the formulation is stable at about 5±3° C. for at least 12 months; and
wherein the stable oral liquid formulation has about 95% w/w or greater of the initial enalapril amount and about 5% w/w or less total impurity or related substances at the end of the given storage period.

US Pat. No. 10,918,619

FORMULATIONS OF PACLITAXEL WITH POLY(AMINO ACID) BLOCK POLYMERS

Tyndall Formulation Servi...

1. A composition comprising paclitaxel and a copolymer of Formula I:
wherein:
x is 175;
y is 30-35; and
z is 20-25.

US Pat. No. 10,918,617

FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS

BANNER LIFE SCIENCES LLC,...

1. An oral immediate release pharmaceutical composition comprising a single phase non-aqueous liquid vehicle comprising a suspension of a fumarate esters or a salt thereof having the formula:
wherein R1 and R2, may be the same or different, and independently represent hydrogen or methyl.

US Pat. No. 10,918,616

FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS

BANNER LIFE SCIENCES LLC,...

1. A method of treating or reducing symptoms of a multiple sclerosis or psoriasis in a subject, the method comprising administering an oral pharmaceutical composition comprising an immediate releasing single phase non-aqueous liquid vehicle comprising a suspension of a fumarate ester or a salt thereof having the formula:
wherein R1 and R2, may be the same or different, and independently represent hydrogen or methyl.